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Parkinson’s disease (PD) is a neurodegenerative disease often characterized at the 
time of diagnosis by resting tremor, rigidity, and/or bradykinesia. Over the course of the 
disease, motor functioning, cognitive functioning, and quality of life typically decline as 
the effectiveness of drug therapies diminishes. This study utilized medical, 
neuropsychological and quality of life data that were collected as part of a double-blind 
placebo surgery trial in which 40 patients were randomly assigned to receive bilateral 
transplantation of embryonic mesencephalic dopamine cells into the putamen or sham 
surgery. Nineteen women and 21 men participated in the study. Analyses focused on 
relationships between neuropsychological, motor, and quality of life data at baseline, 12, 
and 24 months post-surgery. Other analyses investigated differences between older (61+) 
and younger (< 60) patients in regard to neuropsychological functioning, as well as 
neuropsychological differences between those who thought they received the transplant 
and those who thought they received sham surgery at 12 months.   
 Results of this study indicated that a measure of verbal fluency and two measures 
of visual memory correlated most consistently with measures of motor functioning and 
quality of life. Depression was related to lower scores on neuropsychological assessments 
at 12 months and perceived support was related to higher neuropsychological scores at 24 
months. Other results indicated that younger participants obtained higher scores on 
measures of verbal fluency and verbal memory than older participants. Finally, there 
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were no differences between those who thought they received the transplant and those 
who thought they received the sham surgery before the double-blind was lifted at 12 
months in regard to neuropsychological performance. Thus, the placebo effect, which 
was apparent in previous medical and quality of life analyses using these data, did not 
extend to neuropsychological test performance.  
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 Description of Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disease characterized by resting 
tremor, rigidity, and bradykinesia, among other motor deficits. This progressive 
neurological disease results in loss of nerve cells in the substantia nigra and dopamine 
depletion in the striatum (Gilbert et al., 2005).  
PD was first described by James Parkinson in 1817 when he wrote “An essay on 
shaking palsy” in which he presented the onset and progression of motor symptoms. 
Since this essay, medical advances have been made with respect to understanding the 
nature of the disease and subsequent treatment. While several treatments, including 
medication management, have been utilized to slow degeneration of the disease, little 
advancement has been made in the way of a cure.  
 While PD causes motor dysfunction, persons with PD often experience 
neuropsychological deterioration resulting in difficulties in activities of daily living 
(ADL) and quality of life. Areas of neuropsychological dysfunction include verbal 
fluency, verbal memory, immediate memory, learning, visuospatial skills, and executive 
functioning. While neuropsychological abilities decrease as the disease progresses, 
decline in neuropsychological ability can be detected even in early stages of the disease 
(Dubois & Pillon, 1997; Taylor & Saint-Cyr, 1995). To date, neurological assessment and 
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positron emission tomography (PET) scans are the most commonly used tools to assess 
neuropsychological and neurological functioning in PD.  
 Activities of daily living (ADL) are activities related to daily functioning. ADLs  
include activities related to hygiene, mobility, communication, basic bodily functions, 
sleep, work and leisure, and use of personal devices such as glasses, and hearing aids. 
Due to neuropsychological and motor decline in PD, many activities of daily living 
become difficult to perform, sometimes requiring assistance from, if not complete 
dependence upon others for help to complete these tasks. While not every person with PD 
is rendered completely dependent on others, most will experience deficits in several areas 
of ADLs over time.  
 Quality of life (QOL) refers to one’s ability to engage satisfactorily in ADLs and 
to experience global satisfaction with life. Quality of life in persons with PD is an 
important measure of the effectiveness of treatment. While the medical field is constantly 
on a search for a cure of PD, current treatment is focused on slowing the effects of the 
disease and preserving quality of life as long as possible.  
 Medications for Parkinson’s disease 
Treatment of PD begins with medication management. A variety of medications 
are used to treat the disease, which are categorized as dopaminergic and non-
dopaminergic drugs (Schapira & Olanow, 2004). Antiparkinsonian medications are 
prescribed to reduce symptoms of the disease; however, close monitoring of these drugs 
is required as use of the medication can lead to dopaminergic hallucinations and 
psychoses (Siderowf, 2001). 
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 Levodopa (L-dopa) continues to be the most effective and most often prescribed 
dopaminergic agent (Ahlskog, 2001; Lang & Lozano, 1998b). PD patients using L-dopa 
often experience some improvement in rigidity and bradykinesia. While L-dopa has been 
shown to be beneficial, a ceiling effect can be experienced, rendering need for additional 
or alternate medications.   
 Metabolic inhibitors are sometimes used in conjunction with L-dopa in order to 
prolong plasma levels of the medication (Lang & Lozano, 1998b). Decarbozylase 
(Carbidopa) and Catechol-O-Methyltransferase inhibitors (Entacapone) are the two most 
common types of inhibitors prescribed. Bromocriptine, Pergolide, and Apomorphine are 
dopamine agonists that can be helpful in treating early stage PD and can delay the need 
for use of L-dopa (Lang & Lozano, 1998b; McPhee & Stewart, 2001). In addition, these 
medications are used to treat tremor, dystonia, depression, and drug-induced psychosis, 
enhance drug absorption, and reduce oxidative processes in the brain (Ahlskog, 2001). 
 Surgical Treatment for Parkinson’s disease 
When tolerance to medication develops (e.g. the medications become less 
effective), the next step in treatment may be neurosurgery (Honey, Gross, & Lozano, 
1999). Ablation, deep brain stimulation, and fetal cell transplantation are the three most 
common types of surgery used to treat PD (Honey, et al., 1999). While all procedures 
hold promise, fetal cell transplantation is the focus of this study. 
During the 1980s, four patients with PD received transplantation of adrenal 
medulla tissue into part of the brain (Lindvall, 1989). Results from the initial studies 
seemed to hold promise, with subsequent studies supporting these findings and 
demonstrating moderate improvement in approximately 30 percent of the sample (Honey, 
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Gross, & Lozano, 1999). In the late 80s, intrastriatal grafts of fetal dopaminergic neurons 
were performed with modest results (Honey, Gross, & Lozano, 1999; Lindvall, 1989). 
Following these advancements, progress was made with respect to tissue preparation and 
transplant processes (Brundin et al., 2000; Clarkson et al., 1998; Kordower et al., 1995). 
Positive outcomes from these procedures included increased fluorodopa intake, 
exhibition of long-term grafted tissue survival, and some clinical improvement (Brundin 
et al., 2000; Freed et al., 2001; Kordower, Freeman et al., 1995).  
Early transplant studies were largely focused on improvements in motor and 
quality of life. Freed et al., (2001) conducted a study of patients participating in the 
double-blind placebo surgery trial for the treatment of PD. In the double-blind placebo 
surgery trial, patients received bilateral transplantation of embryonic mesencephalic 
dopamine cells into the putamen or sham surgery. Stern and colleagues, part of the 
research group at Columbia University, reported on the neuropsychological aspects of the 
original fetal cell transplant study (Trott et al., 2003). They investigated possible changes 
in cognition from baseline to 12 months following the procedure in the transplant and 
sham groups.  
Statement of Problem 
Because the neuropsychological data were only analyzed from baseline to 12 
months and considered differences only between the real and sham surgery groups, there 
is much still to be learned from these data. One of the most important questions in the 
original study was whether neuropsychological functioning changed over time. As 
described elsewhere in regard to this study (McRae et al., 2004), 12 months was not a 
long enough time to realize all of the changes resulting from the transplant. Thus, it is 
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very important to analyze the neuropsychological data as thoroughly as possible and to 
consider analyses extending out to 24 months in each group; those who originally 
received the transplant and those who first received the sham surgery and then received 
the transplant.  
The current study will continue the analyses of neuropsychological data to assess 
changes in cognition from baseline to 24 months in the group who received the transplant 
surgery and also to examine changes in the group who received the sham surgery first 
and then received the transplant surgery. Instruments were chosen to gather a 
comprehensive picture of neuropsychological functioning in patients receiving bilateral 
transplantation of embryonic mesencephalic dopamine cells into the putamen and those 
receiving sham surgery (Freed et al., 2001). Together, these assessment instruments 
aimed to capture ability for verbal fluency, verbal learning and memory, executive 
functioning, and visual memory.  
Verbal fluency is the ease with which a person uses language, the speed with 
which an individual can make word associations, and the ability to organize verbal output 
(Ostrosky-Solis et al., 2007; Scholtissen et al., 2006). Verbal learning and memory allows 
individuals to store new information that is said to them or that they are able to hear. 
Executive functioning is comprised of capacities that allow an individual to successfully 
engage in independent, purposive, and self-serving behavior and includes mental 
flexibility, ability to assess self and others, and to plan, initiate, and follow through 
among others. Visual memory is the ability to learn and store new information that is 
shown to them or that they are able to see (Lezak, Howieson, & Loring, 2004).   
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The present study will focus on several tests that represent the broad domains 
assessed in the original study. The tests include: the Controlled Oral Word Association 
Test (COWAT; Coelho, 1984; desRosiers & Kavanagh, 1987; Spreen & Strauss, 1991), 
Boston Diagnostic Aphasia Evaluation (BDAE; Goodglass & Kaplan, 1972; Goodglass 
& Kaplan 1983b; Spreen & Strauss, 1991), Digit Span Forward and Digit Span Backward 
subtests of the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Kaufman & 
Lichtenberger, 1999; Strauss, Sherman, & Spreen, 2006; Wechsler, 1981), the California 
Verbal Learning Test (CVLT; Delis et al., 1987; Strauss, Sherman, & Spreen, 2006), the 
Benton Visual Retention Test (BVRT; Benton, 1981; Swan et al., 1990; Whaler, 1956; 
Spreen & Strauss, 1991), and the Wisconsin Card Sorting Test (WCST; Berg, 1948; 
Grant & Berg, 1948; Heaton et al., 1981).  
In addition to the focus on neuropsychological functioning, this study will also 
incorporate and examine relationships between neuropsychological functioning, motor 
functioning, and quality of life at baseline, 12, and 24 months post-surgery in both the 
real and initial sham surgery groups. Motor functioning and severity of symptoms were 
assessed primarily using the Unified Parkinson’s Disease Rating Scale (UPDRS); (Fahn 
& Elton, 1987). Assessment was completed when patients were deemed at their best 
(“on”) and at their worst (“off”). “On” and “off” refer to patients being on and off 
optimal levels of medication, which then affects their physical functioning. Scores on the 
UPDRS were averaged across several administrations at baseline and follow-up. 
Ultimately only the data during the practically defined “off” periods were used. When 
patients were “off” PD medications, they had not taken these particular medications for 
approximately 24 hours. Although data were collected for both “on” and “off” periods, 
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only data from “off” periods were analyzed in this study as UPDRS results during “off” 
times were unaffected by medication changes (Freed et al., 2001). The Hoehn and Yahr 
Stage of Disease Scale (Hoehn & Yahr, 1967), Schwab and England Activities of Daily 
Living Scale (Schwab & England, 1969), and Global Rating of Motor Functioning (Freed 
et al., 2001) were administered during the same times as the UPDRS and were used to 
capture stage of disease and ability to perform ADLs.  
 Quality of life was originally examined in terms of three primary domains: 
Physical Functioning, Emotional Functioning, and Social Functioning (McRae, 2004). 
For purposes of this investigation, only a few scales from the composite variables 
comparing these domains were used. These include the Center for Epidemiologic Studies 
Depression Scale (CES-D); (Hahn et al., 1999; Radloff, 1977), Social Provisions Scale 
(SPS); (Cutrona & Russell, 1987), one item from the Short-Form Health Survey (SF-36); 
(Ware & Sherbourne, 1992), and the “Free or Restricted” item from the original QOL 
questionnaire (McRae et al., 2004). These measures were sent through the mail 
approximately one week after the neurological and neuropsychological assessments.  
Use of Placebo 
Stewart-Williams (2004, p.198) defined the placebo effect as “any genuine 
psychological or physiological response to an inert or irrelevant substance or procedure.” 
Recent biochemical evidence has indicated that the placebo effect in PD patients is 
related to dopamine release in the striatum, which is believed to be triggered by the 
expectation of clinical benefit (de la Fuente-Fernandez, 2004). 
Results of the original study, of which this is a part, showed a strong placebo 
effect in terms of perceived treatment, or the type of surgery patients thought they 
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received. Thus, an additional focus of this study was to analyze the data in terms of 
perceived treatment at 12 months. These analyses were done to examine the influence of 
the placebo effect on neuropsychological functioning. Previous studies have shown that 
the placebo effect can positively influence patients’ quality of life. Therefore, this study 
examined this phenomenon more comprehensively by considering its possible effect on 
neuropsychological data.  
Data Collection and Research Questions 
The original data for this study were collected by Yakkov Stern and colleagues at 
the Taub Institute at Columbia University (Trott et al., 2003). This study served as a 
collaborative investigation between the group at Columbia and this author.  
 Research questions relevant to this study are as follows: 
1) What are the relationships between neuropsychological functioning and QOL 
for real and sham surgery groups at baseline, 12, and 24 months post-surgery? 
2) What are the relationships between neuropsychological functioning and motor 
functioning for real and sham surgery groups at baseline, 12, and 24 months 
post-surgery? 
3) Are there any differences at baseline, 12, and 24 months between older (61+) 
and younger patients (<60) in the domain of neuropsychological functioning? 
4) Are there any differences at 12 months between those who thought they 
received the fetal cell transplant and those who thought they received the 
sham surgery in terms of neuropsychological functioning? 
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Because this study deals with neurological and neuropsychological terms and 
information that are not commonly known, definitions of terms used throughout this 
dissertation are presented below. 
Activities of daily living (ADL): activities related to daily functioning. ADLs include 
activities related to hygiene, mobility, communication, basic bodily functions, sleep, 
work and leisure, and use of personal devices such as glasses, and hearing aids (Wiener, 
J.M., Hanley, R.J., Clark, R., & Van Nostrand, J.F., 1990).   
 
Bradykinesia: general slowness of movement (Paulson & Stern, 2004).  
 
Dopamine: “a neurotransmitter associated with involuntary movement disorders and 
several neuropsychiatric syndromes” (Loring, 1999).  
 
Putamen: “the part of the midbrain involved most prominently in the motor functions of 
the basil ganglia. The putamen is receives afferents from cerebral cortex (primarily motor 
and somatosensory areas), and from the substantia nigra (compact part) and the 
centromedian nucleus of the thalamus” (Nolte, 2002).  
 
Quality of life (QOL): “the characterization of health concern or disease effects on 
patient lifestyle on daily functioning” (Loring, 1999).  
 
Substantia nigra:  “large midbrain nucleus that is often considered part of the basal 
ganglia and is associated with motor functioning. Many cells in the substantia nigra 
contain dopamine and melanin, a byproduct of dopamine metabolism” (Loring, 1999). 
 
Verbal fluency is the ease with which a person uses language, the speed with which an 
individual can make word associations, and the ability to organize verbal output 
(Ostrosky-Solis et al., 2007; Scholtissen et al., 2006).  
 
Verbal learning and memory “acquisition and retention of stimuli that are verbal or 
linguistic in nature” (Loring, 1999).  
 
Executive functioning “cognitive abilities necessary for complex goal-directed behavior 
and adaptation to a range of environmental changes and demands” (Loring, 1999).  
 
Visual memory is the ability to learn and store new information that is shown to them or 
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In summary, this chapter reviewed the nature of Parkinson’s disease, treatment,  
domains commonly affected by the disease, and previous research that has been 
conducted and that inspired the current study. Trott et al., 2003 examined data from 
baseline to 12 months post-surgery and this author was interested in examining additional 
changes over time. This study is an important contribution to the literature on treatment 
of Parkinson’s disease. Studies such as this offer direction related to appropriate medical 
intervention and its influence on overall functioning and quality of life in persons with 
PD.  
 Chapter II will discuss literature related to PD, including neuropsychological 



















Overview of Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disease resulting in 
declines in neuropsychological and physical functioning as well as quality of life. The 
neurodegenerative aspect of PD includes domaminergic cell loss in the substantia nigra 
and the presence of Lewey bodies, which project to the striatum (Hague, Klaffke, & 
Bandmann, 2007; Kish, et al., 1988; Rongve, & Aarsland, 2006).  This dopaminergic cell 
loss results in motor symptoms, which have become characteristic of the disease and 
include resting tremor, cogwheel rigidity, bradykinesia, postural instability, and problems 
with gait (Geng, Li, & Zee, 2006). The motor symptoms develop over time and often 
increase in intensity. Changes in motor symptoms and functioning pose challenges to the 
individual and can affect overall quality of life.  
Results of studies using neuropsychological testing have found 
neuropsychological deficits in individuals with PD even in early stages of the disease 
(Dubois & Pillon, 1997; Taylor & Saint-Cyr, 1995). Due to neurological degeneration, 
overall neuropsychological impairment occurs in individuals with PD and greatly 
increases the likelihood of dementia. Psychotic symptoms may also be present and are 
often regarded as concerning features of dementia and include delusions and 
hallucinations (Rongve & Aarsland, 2006). 
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Both cortical and subcortical deficits are seen in individuals with Parkinson’s 
disease. These deficits are evidenced by reduced speed and attention, impaired working 
memory, poor performance on executive and visuospatial tasks, memory and language 
problems. While stages of disease tend to progress in a sequential manner, 
neuropsychological profiles of individuals with PD vary throughout the stages (Rongve 
& Aasrsland, 2006; Hoehn & Yahr, 1967). Although the cause of PD is unknown, many 
treatments have been developed to address the symptoms of the disease. 
History of Parkinson’s disease 
 Dr. James Parkinson first brought attention to what is now known as Parkinson’s 
disease in 1817 with his essay entitled “An essay on the shaking palsy.” Dr. Parkinson 
wrote about his observations related to onset, slow progression of, and the asymmetrical 
presentation of symptoms, which he noted most often began in the hand or arm. Dr. 
Parkinson commented on the fact that individuals with the disease often did not seek 
medical attention until later stages of the disease. Throughout Dr. Parkinson’s essay, he 
explained and described symptoms such as insidious onset, resting tremor, asymmetric 
weakness and tremor (often in the hand or arm), postural instability, akinesia, gait 
difficulty, sleep disturbance, loss of fine motor skills, decrease in ability to perform 
activities of daily living, stooped posture, drooling, and constipation (Parkinson, 1817). 
Even in this early report on the disease, Parkinson noted that the disease most often 
occurred in individuals fifty years of age or older. 
 Throughout the essay, Parkinson described symptoms of the disease that were 
similar to the symptoms of other known diseases at the time while noting differences 
unique to PD. He also briefly reviewed several cases from which he then concluded that 
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the disease stemmed from “a diseased state of the medulla spinalis”, which has greatly 
influenced today’s research of the disease. He concluded this now famous essay with his 
hopes to find effective treatments and/or a cure for the disease. It seemed that even then 
he understood the challenges that were ahead. 
 James Parkinson’s work inspired further research and led to Charcot’s more 
exacting exploration into the symptoms of “shaking palsy.” In 1888 Charcot named this 
well-described complex group of symptoms, Parkinson’s disease (Goetz, et al., 2000). 
While research and technology have progressed with regard to understanding and treating 
PD, a cure continues to elude the medical field and those living with the disease. 
Clinical Characteristics and Diagnosis 
 James Parkinson (1817) identified and described most of the characteristics still 
used today to diagnose the disease. Of the many motor symptoms, resting tremor, 
rigidity, and bradykinesia are regarded as the hallmarks of PD. Additional motor 
symptoms include akinesia, postural instability, loss of fine motor skills, oculomotor 
abnormalities, blink rate, facial mask, freezing, and speech abnormalities (Gelb, Oliver, 
& Gilman, 1999). These symptoms can cause discomfort and disability.  
Up to 90 percent of patients with PD experience resting tremor (Gelb et al., 1999; 
Lang & Lozano, 1998a). Resting tremor is most obvious when the patient is in 
nonstanding positions such as sitting or reclining and is agitated by stressful conditions. 
Temporary breaks in resting tremor can be experienced and typically are due to voluntary 
movement. Tremors are not present during sleep (Bunting-Perry, 2006).  
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Rigidity is defined as resistance to passive movement while extending and flexing 
through entire range of movement and is experienced by up to 99 % of PD patients 
(Bunting-Perry 2006; Gelb, et al., 1999).  
Bradykinesia is slowness of movement or the inability to move quickly. With 
progression of the disease, akinesia becomes more common and describes the inability to 
initiate and/or maintain movement (Siderowf, 2001). 
PD is often described using stage criteria as defined by Hoehn and Yahr (1967). 
Hoehn and Yahr used the symptoms identified by Parkinson (1817), along with further 
clinical research to define the stages of disease that are used widely today. The Unified 
Parkinson’s Disease Rating Scale (UPDRS) is a commonly used measure, which assess 
severity of typical symptoms of the disease.  
 Parkinson (1817) noted that onset of symptoms can often be asymmetrical and 
begin in one hand or foot in the form of a tremor. The tremor then often affects other 
body parts on the same side of onset (ipsilaterally) and will then move to the opposite 
side of the body (contralaterally) (Siderowf, 2001).  Siderowf reported that up to 40 
percent of PD patients also experience numbness, tingling, aching, and muscle soreness.  
In addition to motor symptoms and discomfort, between 74% to 98% of patients 
experience sleep disturbance. This disturbance can present as excessive daytime 
sleepiness, insomnia, rapid eye movement (REM) sleep disturbance, and restless legs 
syndrome (RLS); (Siderowf, 2001).  
 Neuropsychological Impairment  
The neurodegenerative nature of PD often leads to neuropsychological 
impairment and psychiatric symptoms. With progression of the disease and age of 
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patient, the risk of neuropsychological impairment and dementia increases. Overall 
neuropsychological impairment can be found even in patients newly diagnosed with PD. 
Muslimovic ́, Post, Speelman, and Schmand (2005) conducted a study to determine the 
profile of neuropsychological dysfunction in newly diagnosed PD patients as compared 
to healthy controls. Of 129 potential participants, several were excluded due to refusal, 
stroke, difficulties with comprehension, and global neuropsychological deterioration, 
leaving 115 participants to participate and compare with 70 healthy controls. The Unified 
Parkinson’s Disease Rating Scale was utilized to rate motor symptoms, the Hoehn and 
Yahr Stage of Disease Scale was utilized to determine stage of disease, and the Schwab 
and England Activities of Daily Living Scale was utilized to capture aspects of daily 
functioning. Many neuropsychological assessments were administered to the participants 
including the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Test, 
Trail Making Test Part A, Stroop Colour Word Test Part A and B, an adapted version of 
the WAIS-R Forward and Backward Digit Span, Boston Naming Test (BNT), Visual 
Association Test (VAT), Modified Wisconsin Card Sorting Test (MWCST), Controlled 
Oral Word Association Test (COWAT), and the Judgment of Line Orientation test 
(JOLO). Additionally, the Hospital Anxiety and Depression Scale (HADS) was used to 
capture affective disturbances.  
 Results of the study indicated the presence of neuropsychological dysfunction in 
PD patients particularly in the areas of memory, attention, and executive function. In 
general, PD patients performed lower on the neuropsychological assessments than 
controls, with the Digit Symbol Test differentiating PD patients from controls most 
effectively. Authors also found that the degree of neuropsychological dysfunction was 
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not associated with severity of any of the cardinal motor symptoms of the disease 
(bradykinesia, tremor, and rigidity). This was evidenced by the fact that patients 
exhibited neuropsychological decline without worsening of physical symptoms. The 
authors reported that this finding suggests that neuropsychological neuropathological 
changes are different from those responsible for motor functioning. This finding 
facilitated greater understanding of neuropsychological decline in PD patients as well as 
delineation of neuropsychological and motor processes. 
The importance of assessing verbal fluency in PD patients was explained by 
Abernathy, Donovan, Mcdowall, and Siegert (1999). The authors reported that there are 
four neuropsychological processes that are involved in such tasks. These four processes, 
as described by Auriacombe, Grossman, et al. (1993), are attention and vigilance, a 
lexical or semantic store, a retrieval mechanism, and working memory. The authors 
further reported that it can be difficult to isolate the particular processes at work during 
verbal fluency tasks because they are not directly observable or quantifiable. Therefore, 
the study by Abernathy, Donovan, Mcdowall, and Siegert was designed to focus on 
clustering and switching to better differentiate processes. This decision had been 
preceded by the work of Troyer et al. (1997) who suggested that clustering involves 
accessing a word store while switching involves search processes. Therefore, the four 
identified processes of attention and vigilance, a lexical or semantic store, a retrieval 
mechanism, and working memory can be assessed through focus on clustering and 
switching. The authors defined clustering as generation of words that share a semantic or 
phonemic similarity while switching was defined as the ability to shift between the 
clusters. 
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 Thirteen PD patients were compared with eleven healthy controls on a semantic 
and a phonemic verbal fluency task to assess verbal fluency abilities of clustering and 
switching in PD patients. Comprising the PD subject pool were nine male and four 
female participants between the ages of 45 and 85. The control group consisted of four 
male and seven female participants and ranged in age from 46 to 81. All thirteen 
participants in the experimental group were in early or middle stages of disease as 
described by Hoehn and Yahr (1967). Duration of illness for the experimental patients 
ranged from just under one year to eighteen years with most patients exhibiting motor 
symptoms of bradykinesia and tremor. 
 Prior to verbal fluency tasks, each participant was given the Mini-Mental Status 
Exam (MMSE) and the Wechsler Adult Intelligence Scale-Revised (WAIS-R). Each 
participant was then administered the Controlled Oral Word Fluency Test (COWAT) 
from the Multilingual Aphasia Examination (Benton & Hamsher, 1976). This phonemic 
fluency test required patients to list words beginning with the letters F, A, and S. Patients 
were instructed not to use proper nouns or root words with different suffixes. Sixty 
seconds were given for each list to be completed. Patients were also given the semantic 
naming task, known as the Animal Naming subtest, from the Boston Diagnostic Aphasia 
Examination (Goodglass & Kaplan, 1972). This test required patients to name animals. 
While this test typically allows 90 seconds to complete, the authors shortened the length 
of time to 60 seconds to make it compatible with the COWAT. Before the Animal 
Naming test was given, patients were given a trial test, which required patients to name 
vegetables. The presentation of phonemic and semantic tasks was randomized across 
participants.  
   
 
18 
 Results of this study concluded that PD patients exhibited impairment on both 
phonemic and semantic tasks as compared to healthy controls. The exhibited deficits on 
switching tasks are indicative of PD patients having challenges with retrieval, which is a 
result of dysfunction in the prefrontal cortex. Further, retrieval involves other processes 
such as the ability to monitor words produced, ability to quickly access words when a 
specific category or letter is exhausted, and to disengage from one category and switch to 
a different one. Little difference was seen between the two groups on clustering tasks, 
which depend on intact temporal-lobe functioning. Authors added that the difference that 
was seen may reflect the difficulty for the PD patient in switching and set shifting, but 
that nothing conclusive could be noted. Overall, this study by Abernathy, Donovan, 
Mcdowall, and Siegert (1999) contributed to previous findings supporting deficits in 
frontal and temporal lobe functioning in PD patients as compared to healthy controls and 
brings to light deficits in neuropsychological processes that warrant further examination.  
 Further examination of neuropsychological impairment in PD was done by 
Bouquet, Bonnaud, and Gil (2003) who designed a study to focus on attention and verbal 
fluency. The authors investigated attention and verbal fluency as these tasks are 
correlated with executive functioning in the PD patient, or the ability to organize 
behavioral tasks. They hypothesized that performance on attention and verbal fluency 
tasks may explain neuropsychological resources that relate to executive processes in this 
population. 
 The authors conducted a study, in France, involving 20 patients, 12 men and 8 
women, diagnosed with PD. Severity ranged between stages 1 and 3 as described by the 
Hoehn and Yahr Stage of Disease Scale. These 20 PD patients were compared with 20 
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healthy controls. All participants were administered an adapted version of the Hayling 
Test for French Speakers as described by Burgess and Shallice (1996) to evaluate the 
ability to inhibit a prominent response. The Hayling Test consisted of 28 sentences for 
which the final word was omitted. Sentences were selected with guidance from 
Robichon, Besson, and Faita (1996), who had previously established norms for French 
speakers. In section A of the test, sentences were read to the patient with the expectation 
that the patient would provide an appropriate word to complete the sentence. In section B 
of the test, sentences were read to the patient with the expectation that the patient would 
provide a nonsense word to complete the sentence. In section B, if the patient provided a 
word that related to the sentence, the patient was told that the word was related to the 
sentence, instructions were repeated, and errors documented.  
 Three verbal fluency tasks were completed by each subject and included a 
Phonemic Word Fluency task, a Semantic Word Fluency Task, and an Alternating Word 
Fluency task. The Phonemic Word Fluency (PWF) task required patients to generate 
words with the initial letter M, with further instruction that proper nouns and simple 
variations of words could not be used. The Semantic Word Fluency (SWF) task required 
patients to list animals, and the Alternating Word Fluency (AWF) task required patients 
to generate words from the categories of boys’ names and fruits, with the expectation that 
the patient alternately generate exemplars from each category. Each task was given a time 
limit of 60 seconds. Finally, the Trail Making Test (TMT) was administered as described 
by Lezak (1995), with both Parts A and B given respectively. Part A of the TMT required 
patients to connect numbers in consecutive order while Part B required patients to 
alternately connect numbers and letters in consecutive order; ie., 1, A, 2, B, etc.  
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 Results of the analyses indicated that PD patients exhibited greater latencies on 
both sections of the Hayling Test compared to controls. Notably, both patients and 
controls exhibited the same number of errors on section B, which required completion of 
sentences with a nonsense word. Additionally, PD patients performed poorer on all three 
verbal fluency tasks compared to controls, which may be evidence of impairment in some 
executive processes such as inhibition.  
 Additional exploration of verbal capabilities was conducted by Gilbert, Bherer, 
Belleville, and Chouinard (2005), with a specific investigation of verbal working memory 
in PD patients. The authors assessed 14 non-demented PD patients with 14 matched 
controls to test three areas related to working memory. Most of the experimental 
participants were receiving L-dopa treatment or some related combination of medication. 
Two patients were taking anticholinergic medications only, and one participant was 
unmedicated. The PD participants varied between stages one and three of the disease with 
a mean duration of illness of 7.29 years. The authors were interested in investigating 
decrements in working memory specific to storage deficits and executive impairment, 
relation of reduction in psychomotor speed to working memory deficits, and 
measurement of executive components.  
 All patients were administered the following assessments: an adapted version of 
the Forward Digit Span subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-
R) to assess storage, alphabetical recall test and updating memory (direct) task to assess 
executive function, the Purdue Pegboard test, Digit Symbol Substitution Test (DSST), 
and a reaction time (RT) task to assess motor and psychomotor abilities. Within the 
alphabetical recall test there were two conditions: alphabetical and direct. Participants 
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were read a list of words and then asked to recall them. In the direct condition 
participants were asked to recall the words in the same order as they were given. In the 
alphabetical condition participants were again asked to recall the list of words, this time 
with the added requirement to rearrange them in alphabetical order.   
 Although not statistically significant, results of the Alphabetical Recall test 
showed that PD participants exhibited lower alphabetical recall than direct recall. Both 
groups performed similarly on the Updating Task. Results of the motor and psychomotor 
speed measures revealed the greatest differences between PD participants and controls. 
On the Purdue Pegboard Test, PD participants exhibited significant motor slowing 
compared to controls. Slower performance was also seen in the PD groups on the DSST 
and RT tasks although no statistical differences were found. Overall, authors reported that 
this study indicated that verbal short-term storage in the PD participants was intact as 
evidenced by performance on a digit span task. Performance on a test for updating 
memory was also concluded to be normal. Alternatively, data supported a deficit in 
executive functioning, which was specifically evidenced on a task requiring manipulation 
processes. Finally, motor and psychomotor speed was decreased in experimental 
participants versus controls.  
 Another group of authors investigating verbal working memory deficits were 
Graceffa, Carlesmino, Peppe, and Caltagirone (1999). Specifically, functionality of the 
Articulatory Loop and of the Central Executive during verbal tasks was assessed. Lezak 
et al., (2004) explained that many processes, including decision making, contribute to 
working memory. Therefore, assessing performance on verbal tasks captures an 
important aspect of working memory function in the individual with PD.  
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The authors explained that the Central Executive is comprised of the Articulatory 
loop and the Visuospatial Sketchpad and that these two components are known as slave 
systems. The Central Executive is devoted to reasoning, planning, and to the retention of 
activity of slave systems. The Articulatory Loop also has two components and is a system 
specialized for storage of verbal material. Its subcomponents include the phonological 
store and articulatory rehearsal. The phonological store maintains material in a 
phonological code while the articulatory rehearsal refreshes temporary traces preventing 
decay of stored material. The Visuospatial Sketchpad is a system that is devoted to the 
handling of mental images and to temporarily store visuospatial information. Baddley and 
Hitch (1974) and Norman and Shallice (1986), as cited in Lezak et al., (2004), added that 
in addition to the Central Executive, a supervisory attentional system is also involved. 
Measures of attention are often embedded within assessments of working memory to 
capture performance on the multiple constructs that contribute to working memory.  
 The authors assessed 12 patients presenting with a bilateral form of rigid-akinetic, 
non-demented PD. All patients were on medication and were exhibiting a stable response 
to it. A modified version of a word span test developed by Brizzolara et al. (1993) and the 
Brown-Peterson Paradigm developed by Brown (1958) and Peterson (1959) were utilized 
in this study. The word span test was composed of five word lists composed of sequences 
of strings of two to eight words in length. The first three lists of the test were composed 
of two-syllable words differing for use frequency and phonological similarity. Lists four 
and five were composed of four-syllable, phonologically dissimilar, high and low 
frequency words respectively. During the Brown-Peterson Paradigm participants were 
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asked to recall three consonant strings following 5, 10, and 20 second retention times. 
Retention times were filled by either no concurrent task or by a serial subtraction task.  
 PD patients in this study displayed normal word span performance with no 
reduction due to word length, performing similarly to controls. PD patients also exhibited 
normal phonological similarity and word frequency effects in word span. The authors 
reported that these results demonstrated preserved retention capacity of the phonological 
store and a normal contribution of lexical-semantic knowledge to short-term memory 
tasks, thus supporting normal functioning of the Articulatory Loop in this PD sample. PD 
patients showed normal letter recall on the Brown-Peterson procedure when there was no 
concurrent task during retention time. However, in the presence of the serial subtraction 
concurrent task, PD patients displayed noticeable and premature performance decay 
when compared to controls. Ultimately, results of this study did not support previous 
research suggesting that PD patients experience Central Executive and Articulatory Loop 
deficits.  
 Further examination of verbal memory was done by Ivory, Knight, Longmore, 
and Caradoc-Davies (1999). The authors based their research on previous work using the 
Wechsler Memory Scale (WMS) to identify global patterns of deficits in PD patients. For 
this study, the authors’ objective was to document deficits within a single, well-defined 
sample of non-demented PD patients. Of particular interest to the authors were the areas 
of direct and indirect memory, verbal memory, remote memory, metamemory, and 
awareness of mnestic deficits. 20 non-demented PD patients were compared to 20 
medical control group patients with similar physical disabilities, such as motor slowing 
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and gait. The PD group had a mean age of 70.80 and an average duration of disease of 
5.15 years. The PD patients received standard forms of medical management.  
 Four subtests of the Wechsler Adult Intelligence Scale-Revised (WAIS-R, Digit 
Span, Picture Completion, Similarities, and Arithmetic) were administered to participants 
along with the Controlled Oral Word Association Test (COWAT) to assess for global 
deficits. Additional tests were given to assess for specific types of memory. Indirect and 
direct memory were assessed by focusing on free recall and word completion priming 
and with use of word lists built from the work of Burke et al., (1994). In these tasks, 
participants were asked to complete word stems from two different word lists and to 
recall as many of the ten stimulus words as possible. Verbal memory was explored using 
the Rey Auditory Verbal Learning Test (RVLT) as described by Lezak (1995). In this 
task an original word list was presented with opportunity to recall the words. An 
interference list was then presented with the same opportunity for recall. Finally, 
participants were asked to recall as many words as possible from the original list of 
words. Remote memory was tested with focus on memory for public information using 
The Otago Test of Remote Memory (OTRM). In this task patients were presented with a 
list of 70 famous people spanning many decades. Participants were asked to describe the 
people listed. Metamemory was examined through asking 23 general knowledge 
questions. These 23 questions were extracted from an original pool of 300 designed by 
Nelson and Narens (1980). In this task, participants were asked to answer the general 
knowledge questions and then rate their level of confidence with each answer. Awareness 
of mnestic deficits was assessed following the format of Squire and Zousounis (1988) 
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using 16 questionnaire items asking participants to rate their own ability to recall and to 
maintain attention.  
 Results of this study indicated that on measures of global deficits, only 
performance on Digit Span differentiated PD participants from controls. On average, PD 
participants performed two points below controls, but no clinical significance was 
obtained. PD patients recalled fewer words in the direct memory, free recall tasks. 
However, there were no significant differences between PD participants and controls on 
the indirect memory, word completion task. Upon further exploration of particular trials 
of the RVLT, PD patients exhibited significant impairment on the direct memory, free 
recall task in the incidental learning context. Results of remote memory testing revealed 
no significant difference between groups. However, PD participants exhibited inferior 
performance on items from earlier decades versus later. Upon examination of results 
from the general knowledge, metamemory task, PD and control participants performed 
similarly. Finally, evaluation of confidence ratings on each question to assess awareness 
of mnestic abilities concluded that both groups rated items in a similar manner. 
 In conclusion, this study found that PD participants performed relatively similarly 
to control participants. Only the areas of incidental learning specific to verbal recall and 
remote memory differentiated the PD group. Although statistical significance was not 
obtained, results suggested that mild impairment was present in this particular group of 
PD patients.  
A nonverbal aspect of working memory is visuospatial memory. Postle et al., 
(1997) created a study designed to better understand spatial visual working memory in 
early stage PD patients. Authors used a modified version of a visual delayed response test 
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developed by Smith et al. (1995) during which participants were presented with two 
stimuli and then, after a delay period, were asked to match a probe stimulus to one of the 
two originally presented. Participants were required to match probes to original stimuli 
by proximity (spatial condition) or by similarity (object condition). The stimuli were 
irregular polygons as designed by Attneave and Arnoult (1956) and Vanderplas and 
Garvin (1959). Fifteen PD patients who were determined to be in early stages of their 
disease and fifteen control participants were assessed. One purpose of the study was to 
examine the correlation between side of onset of the disease and performance on the 
research tasks. Eleven of the PD participants had left-side onset leaving only four with 
right-side onset. In the spatial condition, participants responded to probes matching, 
being near to, or far from the original stimuli. In the object condition, participants 
responded to probes matching, being similar to, or dissimilar to original stimuli. All trials 
were conducted through use of a computer allowing for timed presentation of stimuli as 
well as recording of reaction time (RT). In both conditions, spatial and object, perceptual 
and memory tests were embedded within the trials. The Perceptual Test consisted of 
varying exposure of targets on each 20-block trial until the participant was able to 
achieve criterion level performance of 80%-90% correct on two consecutive blocks. 
When this was achieved, the Memory Test was engaged, keeping the exposure time 
determined during the perceptual test and then increasing the delay by 3 seconds. The 
Memory Test consisted of four, 40-trial blocks in each condition. Complete testing took 
place in two sessions, one for object and one for spatial tasks, with several hours between 
the sessions. The order of the sessions was counterbalanced within each group. 
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Results of the Perceptual Test indicated that both groups required longer target 
exposure time to achieve the desired percentage correct in the Object Test versus the 
Spatial Test and that PD participants required longer exposure times than controls in both 
conditions. When evaluating Memory Test results, PD participants and controls differed 
in performance on the Spatial Test but not on the Object Test. Further, control 
participants made significantly fewer errors on the Spatial Test than did PD participants. 
Both groups exhibited faster reaction times for Spatial Memory than for Object Memory 
without significant differentiation between the groups. Finally, the authors examined the 
relationship between side of onset and age with Memory Test performance. Results 
indicated that performance of PD participants on the Memory Test was not affected by 
severity of disease, nor was it correlated with degree of basic motor deficits. However, 
when evaluating complex Motor Functioning, Memory Test performance appeared to 
vary. Understanding that the PD subject pool was unequal with respect to side of onset, it 
did not appear that side of onset affected performance on the Memory Test.  
To conclude, results from this study indicated that individuals with PD exhibited 
spatial memory deficits when compared to controls. Results also suggested that spatial 
delayed response of PD patients on this type of memory test cannot be attributed to basic 
motor deficit or severity of disease. Analyses of the data supported the idea that visual 
working memory is comprised of two material-specific systems. One system is 
responsible for storing and manipulating memory for locations in space while the other is 
responsible for  storing and manipulating memory for the features of objects.  
Kemps, Szmalec, Vandierendonk, and Crevits (2004) examined visuospatial 
processing in PD with particular interest in locus of such deficits. The authors were 
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interested in assessing visuospatial deficits while working to determine if the deficit is 
most related to the Central Executive or the Visuospatial Sketch Pad. As previously 
described, the Central Executive is a system responsible for selecting and updating 
information, inhibiting stereotyped responses, and the coordination of simultaneously 
performed tasks (Kemps et al., 2004). The Visuospatial Sketch Pad is a slave system to 
the Central Executive and is involved in temporary storage and processing of verbal and 
visuospatial information. Authors utilized three tasks in this study: the Corsi blocks task, 
a concurrent Visuospatial Sketch Pad task, and a concurrent Central Executive task to 
assess these systems in persons with PD.  
The Corsi blocks task (Milner, 1971) requires participants to recall increasingly 
longer sequences of spatial locations of blocks. The experimenter touches a sequence of 
blocks and requests that the person reproduce the sequence by touching the blocks 
themselves. The concurrent visuospatial task requests that participants repeatedly tap four 
keyboard keys with their dominant hand while looking at the Corsi block display. The 
concurrent Central Executive task requests participants to press a space bar in response to 
hearing random beeps. All participants completed the Corsi block task first, followed by 
the spatial tapping and random interval tasks, which were counterbalanced across 
participants.   
Fifteen PD participants were compared with 15 healthy controls across 
assessments. Both groups ranged in age from 60-75. Those with PD had an average 
duration of illness of 11.93 years and ranged between stages one and three of illness. 
Results indicated no significant differences between experimental and control groups in 
performance of the concurrent spatial tapping and random interval repetition tasks. Upon 
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examination of data from the Corsi block task, PD participants recalled fewer trials 
correctly. Data analysis of recall scores for PD patients revealed significant stage by 
concurrent task interaction. Specifically, stage 1 patients’ recall performance was most 
adversely affected by the random interval repetition task while the recall performance of 
participants in stages 2 and 3 was most adversely effected by spatial tapping. Authors 
also evaluated the effect of age on tasks, finding that within the PD group, age 
significantly correlated with performance on the Corsi Block task, which was not the case 
in the control group. 
Ultimately, this study of working memory deficit specific to Visuospatial Sketch 
Pad and the Central Executive found that PD patients performed worse than controls on 
the Corsi Block task. Also, PD patients showed deficits on recall tasks with data analysis 
showing that age significantly and adversely affected performance compared to healthy 
controls. These results suggest that impaired visuospatial processing in PD results from 
dysfunction in both the Visuospatial Sketch Pad and the Central Executive. These deficits 
are related to dysfunction in the prefrontal-basal ganglia circuit. Results also showed that 
for PD patients, performance on the Corsi Block task was impacted by stage of disease. 
Taken together, these results suggest that Central Executive deficit is more prominent at 
disease onset while Visuospatial Sketch Pad deficits emerge in moderate stages of the 
illness. Also, because of the significant impact of age in the PD group, it can be inferred 
that PD patients are more susceptible to neuropsychological aging than healthy controls.  
Cronin-Golomb and Braun (1997) designed a two part study to investigate 
visuospatial dysfunction and problem solving in PD. In this study, 50 PD participants, all 
engaged in varied medication management, were compared with 39 controls. Many 
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assessments were utilized in this study, including tests of problem-solving, visuospatial 
performance, executive function, and verbal memory.  
The Raven’s (Coloured) Progressive Matrices (RCPM) task was utilized to assess 
problem solving. The assessment was designed by Raven (1965) and is comprised of 
three subtests. Subtest A consists of items that are solvable through visual closure and is 
described as having problems in the continuous pattern. Subtests Ab and B move from 
closure problems to those in which symbols are used in an analogies test. Several 
additional visuospatial tests were used in the study to assess spatial cognition and 
visuoconstructive function (figure copying). Luria’s Mental Rotation Test required 
participants to select one square from a four choice array that matched a rotated sample. 
The Standardized Road-Map Test of Direction Sense required participants to trace a 
dotted pathway on a map and indicate the direction at each turn. The Geometric Figures 
Test was developed by the researchers and required participants to copy one simple and 
one complex geometric figure. A recall condition took place ten minutes after the original 
presentation and required participants to redraw the original two shapes.  
Executive function was measured with a number of assessments. Symbolic 
fluency was assessed by requiring participants to name as many words as possible that 
began with the letters S and F with each trial limited to 60 seconds. Semantic fluency was 
assessed by requiring participants to list as many members as possible in 60 seconds 
within the categories of vegetables and four-footed animals. The Stroop Color-Word Test 
was utilized to assess set-shifting ability. .A mixed condition was included which 
required participants to look at a stimulus with which incongruent color names were 
written and name as many ink color as possible based on the stimulus. The Picture 
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Arrangement Test of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) was used 
to assess concept formation.  
Verbal memory was assessed with the paragraph (story) subtest of Randt, Brown, 
and Osborne’s Memory Test. Participants read a short story and after ten minutes were 
asked to report verbatim as much story content as possible. They were then required to 
answer questions about the story by choosing correct statements from a four choice array. 
Additional assessments utilized were the Benton Visual Recognition Test (BVRT) to 
assess visuospatial memory and the Boston Naming Test. The subtest of the BVRT that 
was used consists of presenting participants with a complex design for 10 seconds after 
which they are required to choose the target from a four-choice array. The Boston 
Naming Test examines participants’ ability to name objects and animals represented by 
line drawings.  
In the first part of the study, authors examined performance on the RCPM alone. 
Results indicated that PD participants performed significantly worse on Subtest B than on 
Subtests A and Ab with undifferentiated results on these two tests. This outcome 
indicated that PD participants had left hemisphere (analogic reasoning) dysfunction. 
Part two of the study examined the relation of performance on the RCPM with the 
other neurological tests. Overall, PD participants performed more poorly than controls. 
Authors utilized composite scores using multiple regression analysis to predict 
performance on the RCPM. The executive function composite score predicted 
performance on subtests Ab and B of the RCPM and the verbal memory composite score 
predicted performance on subtest B of the RCPM for PD participants. After running the 
same analyses for control participants, no composite scores were successful in 
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significantly predicting performance. The analyses required that the best three predictors 
of performance on Subtest A of the RCPM were the BVRT, Picture Arrangement and 
Road Map Tests. The Boston Naming Test, animal naming, and Picture Arrangement 
were significant predictors for performance on Subtests Ab and B. Authors then took a 
final step of reducing the analysis to only those significant predictors to conclude final, 
and most powerful, predictors of performance on the RCPM. The Road Map Test 
emerged as the only significant predictor of performance on Subtest A for PD 
participants. The Boston Naming Test, fluency-animals, and Picture Arrangement 
remained significant predictors of performance on Subtest Ab. The Boston Naming Test 
and Picture Arrangement were the only significant predictors of performance on Subtest 
B. Authors reported no evidence of multicolinearity. Results indicated that for PD 
participants, the visuospatial composite score was predictive of performance on Subtest A 
while the executive function composite score was predictive of performance on Subtests 
Ab and B. 
In summary, when examining problem solving in persons with PD, impairment 
was exhibited and explained at least in part, by visuospatial deficit. Authors aimed to 
understand the relationship of the RCPM with other neurological tests and concluded that 
other tests were predictive of performance in the RCPM.  
Learning is another important area of neuropsychological functioning in PD.  To 
investigate the role of implicit learning and the degree to which it is either impaired or 
preserved in persons with PD, Siegert, Taylor, Weatherall, and Abernathy (2006) 
conducted a meta-analysis. The authors reported that implicit learning is inferred when an 
individual’s performance on a particular task greatly exceeds their ability to provide a 
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verbal account of the skill. Examples of skills with which implicit learning is present are 
juggling, driving, and riding a bicycle. Implicit or procedural learning is of interest 
because of the role the basal ganglia plays in the process and because of the neuro-
degeneration that takes place in the basal ganglia in PD patients. Authors were 
particularly interested in studies examining implicit learning assessed with serial reaction 
time (SRT) tasks. The authors reported that SRT tasks are the most frequently used 
experimental task to examine implicit learning in PD. During SRT tasks designed by 
Nissen and Bullemer (1987) along with Stadler and Frensch (1998), participants are 
required to press one of four keyboard keys, each key corresponding to a stimulus 
appearing on a computer monitor. Stimuli are presented in any one of four locations on a 
computer screen with varying lengths of speed of presentation. The participants must 
then press the key corresponding with the location of the stimulus. Research on implicit 
learning measured by SRT have yielded inconsistent results, which led the authors to 
conduct the meta-analysis.  
After searching several electronic databases for studies that included use of 
control groups, along with other inclusion criteria, Siegert, Taylor, Weatherall, and 
Abernathy analyzed the data from six studies published between 1999 and 2004. While 
many more studies have been published on this particular topic, a wide variety of 
experimental methods were utilized making them unsuitable for inclusion. Taken in total, 
data for 67 PD patients and 87 healthy controls were analyzed. The mean age of PD 
patients was 60 years of age and the mean age for the healthy control group was 61 years 
of age. Results of the meta-analysis showed that implicit learning was impaired in PD 
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patients as compared to healthy controls. This impairment supports the idea that the basal 
ganglia plays an important role in implicit learning and suggests that the  
neurodegeneration experienced by PD patients is linked with deficits in this area.  
Price (2006) investigated explicit category learning in PD patients. Explicit 
category learning is one process by which individuals organize encountered events and 
objects. Previous research has shown that PD patients exhibit impaired explicit category 
learning performance. The authors reported that one of the most frequently utilized 
assessments in this area is the weather prediction task, (Gluck & Browser, 1988), which 
was utilized in this study along with several other neurological assessment tools. Also 
included was the COWAT, which assessed verbal fluency. The WCST was utilized to 
assess set shifting ability, which was determined by perseverative errors. The WCST was 
also used to assess the consistency with which individuals apply a particular rule, which 
is determined by nonperseverative errors. The Computation Span (CSpan) task was used 
to assess working memory capacity. Finally, a categorization task was also used which 
required participants to assign a math or verbal label to a cue combination which was 
followed by feedback indicating accuracy of the label. Included in the task were blank 
trials in which no feedback indicating accuracy is given. Sixteen PD patients with an 
average disease duration of 8.2 years who were medically well managed were compared 
to 17 matched controls.  
Results indicated that while explicit learning deficits were present, it did not 
appear that these deficits were related to working memory capacity. When analyzing 
errors made throughout the tasks, results indicated that PD patients could maintain 
information in the working memory, but that they had difficulty monitoring this 
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information when feedback was given. PD participants did not evidence difficulty with 
set shifting.  
Overall, results showed deficits in PD patients on explicit learning tasks specific 
to category learning, problem-solving, and monitoring information. Further, authors 
concluded that performance impairments evidenced by the PD group suggested 
dysfunction in the anterior cingulate which is congruent with previous research indicating 
that dopamine projections from the ventral tegmental area to the anterior cingulated are 
damaged in PD patients (Bruck, Aalto, Nurmi, & Rhine, 2005; Grossman, Crino, 
Reivich, & Stern, 1992). 
Taken together, it appears that PD patients experience more deficits in 
neuropsychological functioning than appropriate control groups across a variety of 
neuropsychological domains. Several treatments are available to persons with PD 
including medication and fetal cell transplant. These treatments are intended to slow 
disease processes, maintain functioning, and quality of life.  
Treatment 
 Current treatment for PD is based on palliative care and includes physical therapy, 
mental health therapy, medications, and neurosurgery (Fahn, 1998). Reuter, Engelhardt, 
and Stecher (1999) reported that physical therapy and sports-related activity utilized at all 
stages of the disease helps to maintain physical functioning. Mental health therapy can be 
beneficial to assist patients and families cope with and adjust to the disease and its 
changes over time.  
 
 




Medications are utilized frequently for treatment of PD. There are many 
medications used to treat the disease, which exist within the categories of dopaminergic 
and non-dopaminergic drugs (Schapira & Olanow, 2004). While antiparkinsonian 
medications are often prescribed to reduce symptoms of the disease, use of the 
medication can lead to dopaminergic hallucinations and psychoses (Siderowf, 2001). 
 Levodopa continues to be the most effective and most often prescribed 
dopaminergic agent (Ahlskog, 2001; Lang & Lozano, 1998b). Through use of Levodopa 
(L-dopa), as many as 80% of patients show substantial improvement with respect to 
rigidity and bradykinesia. Tremor has also been shown to improve, but with less 
predictability. While L-dopa is quite helpful in decreasing these motor symptoms, it is 
believed that its window of effectiveness spans five to seven years before patients will 
experience a ceiling effect. Also noted is that dyskinesia is the most common long-term 
complication associated with L-dopa (Lang & Lozano, 1998b). 
 Due to the complication of therapeutic effectiveness, metabolic inhibitors are 
prescribed to be used in conjunction with L-dopa in order to prolong plasma levels of the 
medication (Lang & Lozano, 1998b). The benefit of metabolic inhibitors is that they 
reduce the rate at which L-dopa is metabolized, which in turn, increases the length of 
time of therapeutic effectiveness. Decarbozylase (Carbidopa) and Catechol-O-
Methyltransferase inhibitors (Entacapone) are the two most common types of inhibitors 
prescribed. Bromocriptine, Pergolide, and Apomorphine are dopamine agonists that can 
be helpful in treating early stage PD and can delay the need for use of L-dopa (Lang & 
Lozano, 1998b, McPhee & Stewart, 2001). Non-dopaminergic agents are used to treat a 
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wide-variety of PD symptoms, which include tremor, depression, drug-induced 
psychosis, enhance drug absorption, dystonia, and reduce oxidative processes in the brain 
(Ahlskog, 2001). 
 Due to the progressive nature of PD, patients may build tolerance to medications 
over time rendering them less effective. When this occurs, the next step in treatment may 
be neurosurgery (Honey, Gross, & Lozano, 1999). Ablation, deep brain stimulation, and 
fetal cell transplantation are the three most common types of surgery used to treat PD 
(Honey, et al., 1999). While all procedures hold promise, fetal cell transplantation has 
gained recent attention and is the focus of this study. 
Fetal Cell Transplant 
During the 1980s, the first four patients with PD received transplantation of 
adrenal medulla tissue into part of the brain (Lindvall, 1989). Results from the initial 
studies seemed to hold promise with subsequent studies supporting these findings and 
demonstrating moderate improvement in approximately 30 percent of the sample (Honey, 
Gross, & Lozano, 1999). While moderate gains were promising, complications from the 
procedure appeared to outweigh the benefits causing the adrenal medulla grafting to be 
largely abandoned in the late 1980s (Lindvall, 1989).  
In 1987, intrastriatal grafts of fetal dopaminergic neurons were performed with 
modest results (Honey, Gross, & Lozano, 1999; Lindvall, 1989). Following this 
advancement, progress was made with respect to tissue preparation and transplant 
processes (Brundin et al., 2000; Clarkson et al., 1998; Kordower et al., 1995). Positive 
outcomes from these procedures included increased fluorodopa intake, exhibition of 
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long-term grafted tissue survival, and some clinical improvement (Brundin et al., 2000; 
Freed et al., 2001; Kordower et al., 1995).  
Hagell and associates (1999) examined the effects of a second graft of human 
embryonic mesencelephic tissue. Five patients had initially received unilateral 
implantation in the striatum 10-56 months previous to the second graft. The second graft 
then took place and human embryonic mesencelephic tissue was implanted on the 
contralateral side of the brain in the putamen or the putamen plus caudate (received by 
one patient). The Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and 
Yahr Stage of Disease Scale were utilized in the study to assess current functioning along 
with other assessments. Results of the study indicated that all participants benefited from 
the procedure, showing increased flouradopa in the grafted putamen. Additionally, the 
authors concluded that the second grafting in no way interfered with or disrupted the 
original transplantation and that the successful initial transplantation did not disrupt or 
interfere with the second grafting. Four of the five patients receiving the second graft 
(complete bilateral transplantation) showed marked improvement in symptoms of gait, 
speech, and balance. Additionally, two patients were able to withdraw from L-dopa 
medication completely. These findings were notable and supported further research in 
this area. 
With interest in evaluating the long-term effects of fetal cell transplant, Hauser et 
al., (1999) followed 6 patients with advanced PD up to 24 months after bilateral fetal cell 
transplantation. Utilizing the UPDRS and Schwab and England Activities of Daily Living 
Scale to assess for overall functioning, authors found that patients benefited from the 
surgery, showing a mean of 32% improvement in UPDRS scores. Additionally, patients 
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exhibited a decrease in waking day dyskinesia and an overall increase in fluorodopa 
intake. 
As mentioned previously, Freed et al., ( 2001) conducted a placebo-controlled 
clinical trial to further understand the effectiveness of fetal cell transplant. The study 
utilized a double-blind design and patients in the study received either fetal cell transplant 
or a sham (placebo) surgery. Forty patients with PD were recruited for the study. The 
participants ranged in age from 34-75 and were considered to have severe PD, having at 
least two of three main signs including bradykinesia, rigidity, and tremor at rest. All 
patients were determined to have responded to L-dopa and had positron-emission 
tomographic (PET) scans compatible with the presence of PD. Assessments used in the 
study included the Unified Parkinson’s Disease Rating Scale (UPDRS), Schwab and 
England scale, Hoehn and Yahr, and PET scans. 
The UPDRS is a comprehensive inventory of PD symptoms and captures 
information related to mental activity, mood, activities of daily living, motor 
performance, muscle rigidity, speech, and gait. The Schwab and England Activities of 
Daily Living Scale measures performance in activities of daily living with a range of 
normal (100%) to completely disabled (0%). PET scans were utilized to determine the 
survival of fetal cells as evidenced by an increase in fluorodopa uptake.  
Twenty participants were assigned to each group (real and sham) and underwent 
their respective procedures. One patient died in an automobile accident seven months 
after surgery. All participants were examined with PET scans to measure changes in 
neurological functioning.  
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At approximately thirteen months following the surgery, participants were told 
which procedure they had received. Those who had received the sham surgery were then 
offered the option of undergoing the actual fetal cell transplant. Examples of the PET 
scans can be found in Appendix A. 
Results of the study indicated that younger participants were found to benefit the 
most from surgery and that the placebo was relatively strong. Transplant group 
participants showed significant improvement from baseline to 12 months in scores on the 
Schwab and England scale, with the younger patients in the transplant group improving 
significantly more than those in the sham surgery group. Transplant group participants 
also showed improvement on the UPDRS with men scoring significantly better than 
women. PET scans in 17 of the 20 transplant recipients showed survival of transplanted 
cells regardless of age. This finding demonstrates that the cellular and chemical signals 
necessary to support the development of embryonic dopamine neurons were present in 
patients with PD.  
Neuropsychological aspects of the fetal cell double-blind trial were investigated 
by Yakov Stern and others at Columbia University and North Shore University Hospital. 
These researchers focused on neuropsychological performance of the 40 participants in 
the double-blind study. Participants, ranging in age from 34-75 years of age at the time of 
enrollment, exhibited motor symptoms of bradykinesia, rigidity, and/or resting tremor. A 
variety of neuropsychological measures were utilized to analyze neuropsychological 
ability before and one year following surgery. A partial list of the measures included: 10 
designs from Form C of the BVRT, Digits Forward and Backward from the WAIS-R, 
CVLT, COWAT, BDAE, and the WCST.  PET scans were utilized to assess cell growth 
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and fluorodopa uptake. The scans were utilized in some analyses, but were not a focus of 
outcomes. Additional measures of functioning related to PD included the Unified 
Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr Stage of Disease Scale and 
the Schwab and England Activities of Daily Living Scale.  
Results indicated that neuropsychological performance did not differ significantly 
between the two groups one-year post-surgical procedure (Trott et al., 2003). Neither 
group showed significant change on most measures from baseline to one-year follow-up. 
When changes were seen, they were more likely to be seen in both groups and could be 
expected due to the neurodegenerative nature of the disease.   
Placebo Effect 
 Stewart-Williams (2004, p.198) defined the placebo effect as “any genuine 
psychological or physiological response to an inert or irrelevant substance or procedure.” 
Recent biochemical evidence has indicated that the placebo effect in PD patients is 
related to dopamine release in the striatum, which is believed to be triggered by the 
expectation of clinical benefit (de la Fuente-Fernandez, 2004). Supporting this notion was 
a study by Pollo et al. (2002) who examined seven PD patients who had received 
subthalamic (STN) deep-brain stimulation (DBS). Results of this study indicated that 
Motor Functioning was better in the patients with expectation for improvement than in 
those expecting deterioration.  
 A study exploring expectation and dopamine release in PD was conducted by de 
la Fuente-Fernandez et al. (2002). In this study the authors utilized PET to estimate 
dopamine release induced by pharmacology or placebo. Specifically, the authors 
examined [11C]raclopride (RAC) binding to D2 and D3 receptors and endogenous 
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dopamine. The authors explained that with decreased RAC binding there is increased 
release of endogenous dopamine in the striatum. Six patients with PD were examined for 
striatal RAC binding potential in two conditions. The first condition was a blinded, 
placebo controlled study. The second condition was an open study with the same patients, 
but without placebo. The drug utilized in the study was Apomorphine, a dopamine 
receptor agonist, and the placebo was saline. Results of this study were indicative of 
decrease in RAC binding potential when patients received the placebo treatment. The 
decrease in RAC biding potential was seen in all patients and all within the striatal 
subregion, with the greatest effect seen in the posterolateral portion of the putamen. The 
authors reported that the magnitude of the placebo response was comparable to 
therapeutic doses of L-dopa or Apomorphine. Additionally, the release of dopamine was 
greater in patients in the placebo condition than those who were not. It appears that the 
placebo effect was mediated by an increase in dopamine release in the striatum and that 
PD patients engaged in drug therapy in the context of a placebo control benefited from 
the drug as well as the placebo effect.  
 In 2004 de la Fuenta-Fernandez and Stoessl published another study related to 
placebo effect in PD using PET scans. In the article studies of double-blind trials of 
Pergolide as treatment for PD were cited. Pergolide is a medication used to treat stiffness, 
tremor, and poor motor control. de la Fuente-Fernandez and Stoessl reported that 
Diamond et al. (1985) compared patients treated with Pergolide with those treated with 
placebo, finding improvement in both groups. Further, the authors reported a study by 
Goetz et al. (2000) who examined patients enrolled in a randomized, placebo-controlled 
clinical trial of Ropinirole monotherapy. Ropinirole is a drug used for restless leg 
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syndrome. de la Fuente-Fernandez reported that Goetz et al. (2000) concluded that 
patients in the placebo condition obtained 50% improvement in all domains of 
parkinsonian disability, noting that bradykinesia and rigidity were more susceptible to the 
placebo effect than tremor, gait, or balance. Like de la Fuenta-Fernandez’s previous 
study, the authors utilized previous results adding the analysis of expectation of reward 
and actual clinical benefit. PET scan information was utilized to objectively measure 
dopamine release in the striatum and the author used previous data showing a strong 
placebo effect. When patients were asked to rate clinical benefit of treatment, only half of 
placebo participants reported clinical benefit in motor functioning. Goetz et al. (2000) 
concluded that dopamine release was triggered by expectation of reward (expectation of 
clinical benefit) rather than the reward itself (perception of clinical benefit). 
Quality of Life 
Little research has been done with respect to quality of life (QOL) and fetal cell 
transplant. However, some research has been conducted on quality of life as it relates to 
PD in general. Martinez-Martin (1998) reported that a common definition of QOL has not 
been agreed upon; however, it is often considered complimentary to duration (quantity) 
of life. The World Health Organization views QOL as an interaction of several domains 
and reported “Health is a state of complete physical, mental, and social well-being and 
note merely the absence of disease or infirmity.” Therefore, while patients with PD 
obtain treatment to control motor and neuropsychological decline, QOL proves to be an 
elusive but important area of focus is certainly influenced by the disease and is often 
influenced by medical treatment.  
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Habermann (1996) surveyed 120 PD patients to assess the day to day demands of 
PD. Results of the study indicated that patients felt that practitioners were not concerned 
with personal issues related to PD and were only interested in prescribing medications. 
Additionally, Habermann concluded that perspectives of medical personnel and patients 
were often incongruent with respect to severity of patient symptoms. This inspired further 
study by Abudi et al. (1997), who found similar results. Studies such as these 
acknowledged discrepancies between patient and medical professional perspectives 
related to experience of symptoms and functioning, underscoring the need to address 
quality of life for PD patients. 
Phillips (2006) designed a qualitative study during which she interviewed six men 
and five women with PD to gather information on emotional responses to being 
diagnosed with the disease and helpful coping strategies. Patients ranged in length of 
diagnosis from 6 months to 15 years, had a mean age of 69, and ranged in stage of 
disease between 1 and 4 according to the Hoehn and Yahr Stage of Disease Scale. The 
authors concluded that while the experience of being diagnosed with PD was different for 
each participant, a general theme of being confused and overwhelmed was shared among 
them. Further, the participants suggested that interacting with other PD patients and 
continued education on the disease were most helpful in adjusting to the disease in 
addition to medication to treat symptoms. Other helpful resources were identified as 
occupational therapy and structured daily activities. Studies like this are essential in 
understanding quality of life in patients with PD.  
Hariz et al. (2003) examined gender differences in relation to disability and health 
related quality of life (HRQoL) pre- and post- Deep Brain Stimulation (DBS). Forty-one 
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PD patients shown to be responsive to L-dopa participated in the study. The participants 
were comprised of 15 females and 26 males. The mean age of the group was 65.7 years 
of age and mean duration of illness was 12 years. 
A structured interview was completed with all participants to assess for patients’ 
expectations regarding the outcome of surgery and perceived side effects. The Mini-
Mental Status Exam (MMSE) was completed to assess for dementia and aspects of 
cognition. The Unified Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr 
Stage of Disease Scale, and Schwab and England Activities of Daily Living Scale were 
used to capture stage of severity of illness, stage of disease, and activities of daily living 
(ADL). The ADL Taxonomy was also used. It is an occupational therapy rating of ADLs 
that assesses the patient’s ability to sequence activities as well as level of independence 
with specified activities. The Nottingham Health Profile (NHP) is a generic instrument 
based on self-assessment of perceived distress related to an individual’s health. The 
Visual Analogue Scale (VAS) was utilized to evaluate the impact of disease on life 
including social functioning. Finally, the Life Satisfaction Questionnaire was used to 
assess overall life satisfaction as well as satisfaction in several domains of life.  
 The authors noted that at the time of surgery, men and women did not differ in 
age, but women had lived with the disease an average of 5 years longer than men. MMSE 
scores were different between genders with scores for men being significantly lower than 
for women both before and after surgery. The scores remained unchanged at pre- and 
post- surgery assessments. Preoperatively, women showed lower (better) scores than men 
on UPDRS part II and part IV as well as on the Schwab and England Activities of Daily 
Living scale pre-surgically. However, these differences disappeared post-operatively. 
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Specific items showing marked improvement for both genders were writing, using knife 
and fork, and severity of tremor. Results on the ADL Taxonomy indicated improvement 
for women, but not for men with preoperative differences persisting postoperatively. 
NHP results indicated only one change postoperative and that was a decrease in 
emotional constraints for women. No differences were seen on the VAS between genders 
at either data point. Life satisfaction overall was different between genders with men 
being more satisfied than women; results did not change post-surgery. With all results 
taken together, both genders exhibited improved quality of life post-surgically with 
women showing the most improvement in the areas of ADL, emotional constraints, and 
social life.   
 To summarize, the authors found that PD patients improved on some measures of 
QOL following DBS.   
 Mood is an important component of quality of life and can directly impact 
performance on ADLs. Depression is a major symptom of PD and is related to the 
decrease in dopaminergic activity as well as a more general emotional response to having 
the disease and experiencing changes in function. While there continues to be some 
uncertainty about the etiology of depression in persons with PD, it is considered to be a 
consistent feature of the disease with estimates of its occurrence ranging from 40% to 
60%. However, it has been reported to occur as much as 70% of the time.(Askin-Edgar, 
White, & Cummings 2002; Bieliaukas & Glantz, 1989; Lieberman, 1998). Treatment 
with L-dopa can improve depression somewhat, but this improvement is largely transient 
and insignificant (Santamaria & Tolosa, 1992). Depression is important to consider when 
examining quality of life in persons with PD. The effects of depression influence all 
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aspects of life including motor functioning and motivation for physical activity, and 
negative thoughts and feelings about self and life. Depression also interferes with 
neuropsychological functioning (Leentjens & Verhey, 2002).  
The hallmark of quality of life is one’s perception that they can participate in 
daily living as they wish. Depression often leads to loss of motivation to engage in 
physical activity and low endurance, which can decrease participation in ADLs. Living 
with depression causes the individual to view themselves, their situation, and life in 
general in a negative way. This, in turn, is linked to significant emotional discomfort and 
disturbance that can compromise many aspects of an individual’s life including 
relationships and motivation for treatment. Finally, depression interferes with attention, 
which is important in learning and memory. Depression also interferes with thinking and 
reasoning as it often skews the individual’s toward the negative, resulting in irrational 
thinking and an inability to reason effectively (Padesky & Greenberger, 1995).  
McRae et al., (2004) participated in the study conducted by Freed et al., (2001) by 
investigating quality of life. The study by Freed et al., (2001) served as a parent study to 
McRae and colleagues. Thirty participants of the original 40 agreed to participate in the 
quality of life study. Of the 30 participants, 12 received the actual fetal cell transplant 
procedure and 18 received the sham (placebo) procedure. McRae et al. examined quality 
of life in three domains, which included Physical Functioning, Emotional Functioning, 
and Social Functioning. Overall, results indicated that participants in both surgery groups 
showed significant improvement in Physical Functioning at 12 months. No differences 
between treatment groups were seen at 12 months in the areas of Emotional and Social 
Functioning.  
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To conclude, quality of life is an important point of consideration when 
evaluating outcomes of medical treatment. While some research has been conducted 
related to PD and quality of life generally, evaluating quality of life outcomes specific to 
fetal cell transplant contributed to knowledge about the perceived benefits of this 
treatment based on patient perspectives.  
Chapter II discussed neuropsychological assessment as an important indicator of 
cognitive functioning in persons receiving embryonic dopamine neuron implantation. 
Over the normal course of PD, diffuse neuropsychological deficits are often seen. There 
is not a typical or expected lock-step sequence of these deficits. Rather, it appears that 
persons with PD ultimately have difficulty with executive functions including the ability 
to shift sets, visual memory, visual perception, and visuo-constructional abilities, verbal 
learning and memory, working memory, and verbal fluency. Neurodegeneration due to 
PD and the aging process may confound results of these assessments. However, 
neuropsychological assessments are the best means of capturing the status and changes in 
neuropsychological functioning over time.  
This chapter also discussed motor functioning and quality of life in persons with 
PD. With progression of the disease, there are expected declines in motor functioning and 
quality of life. Persons with PD experience increases in severity of symptoms including 
resting tremor, rigidity, bradykinesia, among other deficits. Further, PD patients are at 
risk for depression, inability to participate in activities of daily living, and social 
isolation.  
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Chapter III will outline methods of this study including purpose, participants, and 
assessments used to examine neuropsychological functioning, motor functioning, and 
































Purpose of study  
The aim of the current study is to examine longitudinal neuropsychological data 
of patients participating in the double-blind placebo surgery trial for the treatment of PD. 
Twenty patients received bilateral transplantation of embryonic mesencephalic dopamine 
cells into the putamen, and 20 received sham surgery. Patients who received the actual 
fetal cell transplant are referred to throughout the rest of this paper as the “real” surgery 
group. Patients who had the sham surgery are referred to as the “sham” group.  
Stern and colleagues (Trott et al., 2003) focused on possible changes in cognition 
12 months following the procedure. The current study will continue the analyses of 
neuropsychological data to assess changes in cognition from baseline to two years. In 
addition, this study will incorporate and examine data related to motor functioning and 
quality of life at baseline, 12, and 24 months post-surgery. This study will explore the 
relationships between these variables at each data point.  
Participants 
 A total of 40 patients comprised of 19 women and 21 men participated in the 
original study (Table 1). The ages of the patients ranged from 34-75 at the time of 
enrollment. The majority of patients were Caucasian. Patients older than 61 years of age 
were deemed “older” while patients 60 years of age and younger were deemed 
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“younger.” All patients were determined to have idiopathic PD and exhibited at least two 
of the following symptoms: resting tremor, rigidity, and bradykinesia. The range of 
duration of illness was 7 to 21 years with an average duration of 14 years. All potential 
patients were screened with the Mini-Mental State Examination (MMSE) and excluded if 
a score of less than 24 out of 30 was obtained. Other reasons for exclusion included: 
hallucinations or delusions while on L-dopa, major depression, dementia, other severe 
medical disease, previous brain surgery, or evidence of other neurological disorder as 
determined by magnetic resonance imaging (MRI).  





Gender Men 21 
 Women 19 
   






   
Treatment Groups Transplant Surgery 10 younger <60, 9 older 61+ 
 Sham Surgery 11 younger <60, 9 older 61+ 
   
Excluded Data 
 
1 older, 1 younger 
(developed 
dementia prior to 1 
year post-surgery) 
Transplant surgery 
 1 older 
(developed 
dementia prior to 1 
year post-surgery) 
Sham surgery 
 1 older 
(died in car accident 




The original study, as described previously, utilized a number of 
neuropsychological assessments to examine cognition across a broad range of 
functioning. Assessments were related to the commonly affected areas of functioning in 
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PD, including verbal fluency, verbal learning and memory, executive functioning, and 
visual memory.  
Neuropsychological evaluation 
The specific assessment instruments used in this study to assess 
neuropsychological functioning and reviewed below included: the Controlled Oral Word 
Association Test, Boston Diagnostic Aphasia Evaluation, Digit Forward and Digit 
Backward subtests of the Wechsler Adult Intelligence Scale-Revised, the California 
Verbal Learning Test, the Benton Visual Retention Test, and the Wisconsin Card Sorting 
Test.  
 Controlled Oral Word Association Test (COWAT) 
 The purpose of the COWAT is to assess the production of words under restricted 
search conditions; e.g., words that begin with particular letters within a specified amount 
of time, usually 1 minute (Spreen & Strauss, 1991). Test administration consists of three 
trials and takes about five minutes. The score is the sum of all admissible words for the 
letters given and/or the average score across trials. Inadmissible words include proper 
nouns, wrong words (wrong letter), variations of the same word, and repetitions. These 
words are not counted as correct and are not included in the total score.  
Snow et al. (1988) reported both interscorer reliability and one-year retest 
reliability in older adults as .70. desRosiers and Kavanagh (1987) reported retest 
reliability after 19-42 days in adults as .88. Coelho (1984) reported that concurrent 
validity has been established in several studies.  
In this study, the COWAT was used to assess verbal fluency and required patients 
to list as many words as possible beginning with particular letters within a one minute 
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time frame for each letter. English speakers were asked to generate lists beginning with 
the letters of C, F, and L and Spanish speakers were asked to generate lists beginning 
with the letters of P, S, and V.  
Boston Diagnostic Aphasia Evaluation (BDAE)-2 
 The Boston Diagnostic Aphasia Evaluation is used to comprehensively assess 
language functioning (Spreen & Strauss, 1991). Goodglass and Kaplan published the first 
edition in 1972 and a second edition in 1983 (Goodglass & Kaplan, 1983b). The second 
edition was utilized in this study. The assessment is organized into five sections 
including; conversational and expository speech, auditory comprehension, oral 
expression, understanding written language, and writing (Spreen & Strauss, 1991).  
Estimates of reliability of the test is reported to range from greater than .95 for Sentence 
Repetition to less than .65 on measures of Auditory Comprehension. 
 In this study, only the animal naming subtest of The Boston Diagnostic Aphasia 
Evaluation was utilized. This subtest was employed in conjunction with the COWAT to 
assess verbal fluency. The test required patients to list as many animals as possible within 
a one minute time period.  
Wechsler Adult Intelligence Scale-Revised (WAIS-R) 
The WAIS was first published in 1939 as the Wechsler-Bellevue Intelligence 
Scale and has since gone through several revisions. The WAIS-R has been widely used to 
assess general intelligence, neuropsychological potential, and neurological dysfunction 
(Kaufman & Lichtenberger, 1999; Strauss, Sherman, & Spreen, 2006). The WAIS-R was 
used in the original study as assessments begin in 1995, before the publication of the 
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current version, WAIS-III. The following information pertains to the WAIS-R because of 
its use in the original study.  
Scoring of the WAIS-R is reported in terms of the three main scales of Full Scale 
IQ (FSIQ), Verbal IQ (VIQ), and Performance IQ (PIQ). Digit Span Forward and 
Backward are subtests that capture working memory performance. The WAIS-R manual 
reported reliability coefficients for all subtests, VIQ, PIQ, and FIQ across age ranges as 
well as overall reliability averages for each subtest. The average reliabilities for the 
subtests are as follows: Digit Span .83, VIQ .97, PIQ .93, and FIQ .97 (Wechsler, 1981).  
Test-retest reliability was also averaged across age groups and reported for age 
groups 25 to 34 and 45 to 54. Test-retest reliability for the Digit Span subtest was 
reported to be .89 for age group 25 to 34 and .82 for age group 45 to 54. Wechsler (1981) 
did not report specific validity coefficients. Instead, the author reported that the validity 
of the WAIS-R could be considered as similar to previous versions of the test.  
The Digit Span Forward subtest of the WAIS-R captured patients’ immediate 
verbal memory while the Digit Span Backward subtest of the WAIS-R assessed patients’ 
working memory. Both subtests required patients to remember and repeat several trials of 
a series of numbers of increasing length read to them by the examiner. Digit Span 
Forward required participants to repeat the numbers as read to them in exactly the same 
order while Digit Span Backward required participants to repeat the numbers in the 
opposite order as read to them by the examiner.  
California Verbal Learning Test (CVLT) 
The CVLT, often described as a list-learning task, was used to measure verbal 
learning and memory (Delis et al., 1987) and was utilized for this study. The test has been 
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revised since its original publication to accommodate new developments in the field and 
to address concerns raised about the first edition (Strauss, Sherman, & Spreen, 2006). 
The CVLT was used in the original study as assessments began in 1995, before the 
publication of the most current version, CVLT-II. The following information will pertain 
to the CVLT because of its use in the original study.  
Delis et al. (1987) reported internal consistency and test-retest reliabilities for the 
CVLT. Internal consistency was reported for four areas specific to List A and included: 
five trial scores “a,” semantic categories “a,” item totals across five trials “a,” and item 
totals across five trials “b.” Authors reported internal consistencies of .92 for five trial 
scores “a,” .74 for semantic categories “a,” .69 for item totals across five trials “a,” and 
.86 for item totals across five trials “b.”  
Validity coefficients were not directly reported in the CVLT manual. Rather, the 
authors stated that results of factor analyses indicated that the multiple indices cluster into 
theoretically meaningful factors and that they are consonant with the constructs they were 
designed to measure. Authors addressed criterion-related validity by reporting that the 
correlations between the CVLT raw scores and Wechsler Memory Scale (WMS) scores 
were significant 64% of the time at the .05 level. Also, Delis et al. (1987) reported that 
the total immediate recall of List A across the five trials and the WMS Quotient achieved 
a correlation of .66 and in the .”60s” with several other WMS variables.  
In the CVLT manual, Delis et al. (1987) reported that the CVLT “measures both 
recall and recognition of word lists over a number of trials.” In this study, patients were 
presented with 16 words, four from each of four semantic categories, over five trials. 
After an interference list was presented, the patient was then asked to recall the first list 
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of words. There was then a 20 minute delay after which the patient was asked to again 
recall the first list of words. A form was used by the examiner to administer the test and 
record answers. This form, along with the manual, facilitated scoring of the test once 
completed. Scoring of the CVLT involved attention to classification of responses, correct 
responses, number of correct words, number of intrusions, and correct semantic cluster.  
Benton Visual Recognition Test (BVRT) 
The purpose of the BVRT (Benton, 1981) is to assess visual memory, visual 
perception, and visuo-constructive abilities. There are several forms of the test, a variety 
of options for administration (that fall within drawing administration and multiple-choice 
administration), and several options for scoring, depending on the objective of the 
assessment (Spreen & Strauss, 1991). Multiple-choice and matching administrations were 
used in this study.  
Swan et al., (1990) and Wahler (1956) reported that for drawing administrations 
of the test, interscorer agreement for number correct and total error is above .95. Benton 
(1974) reported that overall, alternate form reliability is good with coefficients ranging 
from .79 to .84 between the three forms of the test. For multiple-choice administration, 
Benton (1981) reported that alternate-form reliability is .80 and split-half reliability is 
.76. 
Wisconsin Card Sorting Test (WCST) 
Finally, the purpose of the WCST is to assess the ability to form abstract concepts 
and to shift and maintain sets. It was developed by Berg (1948) and Grant and Berg 
(1948). The test provides information on several aspects of executive functioning 
including problem-solving behavior and is especially sensitive to lesions of the frontal 
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lobe. Test instructions and scoring procedures for the long version were formally 
published as a clinical instrument by Heaton et al. (1981). Milner (1963) reported that 
clear differences between patients with dorsolateral frontal excisions and those with 
orbitofrontal and posterior lesions were found in her study. Further, conclusions from 
several studies have suggested that the WCST is particularly sensitive to frontal lobe 
function (Bornstein, 1986; Drewe, 1974, Hermann et al., 1988, Robinson et al., 1980). 
Heaton (1981) reported interscorer reliability as excellent with correlation 
coefficients of .93 for Perseverative Responses, .92 for Perseverative Errors, and .88 for 
Nonperseverative Errors. Heaton (1981) also reported intrascorer reliability to be 
excellent with correlation coefficients of .96 for Perseverative Responses, .94 for 
Perseverative Errors, and .91 for Nonperseverative Errors. Heaton (1981) described 
several studies that have been conducted with the WCST with a variety of populations, 
concluding that the test is valid and reliable.    
The WCST consists of four stimulus cards and 128 response cards depicting 
figures of varying forms. The forms include crosses, circles, triangles, or stars. The colors 
include red, blue, yellow, or green. Finally, the number of figures on each card varies 
between one and four. Administration of the test consists of the patient being presented 
with four stimulus cards and being given a deck of 64 cards to match with the stimulus 
cards. The patient is instructed to match the cards from the deck with the stimulus cards. 
The patient is told only whether each response is right or wrong, but is never told the 
correct sorting principles, which consisted of color, form, and number. After 10 
consecutive correct matches, the sorting principle changes, but with no information to the 
patient other than that their attempt to match was right or wrong.  
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Scoring of the WCST was done by following instructions offered in the 
administration manual and calculating the number of categories completed, trials to 
complete the first category, percent of perseverative errors, failure to maintain set, and 
percent conceptual level responses.  
Motor Functioning 
The specific assessment instruments used in this study to assess motor functioning 
and reviewed below included: the Unified Parkinson’s disease Rating Scale (UPDRS), 
Hoehn and Yahr Stage of Disease Scale, Schwab and England Activities of Daily Living 
Scale, and a Global Rating of Motor Functioning.  
 Unified Parkinson’s Disease Rating Scale (UPDRS) 
Severity of disease was assessed using the Unified Parkinson’s Disease Rating 
Scale (UPDRS), which is a standard assessment instrument that was used in the parent 
study. One of the most important subscales of the UPDRS assesses motor functioning. 
Both the total score, which covers a wide range of domains, and the motor score were 
included in analyses. Assessment was done when patients were deemed at their best 
(“on”) and at their worst (“off”). “On” and “off,” refer to patients being on and off 
optimal medication levels. For example, when someone is “on,” he or she is functioning 
as well as possible at his or her particular stage of disease. When a person is “off,” 
functioning is diminished and he or she may be partly incapacitated until the next dose of 
medication takes effect.  Scores on the UPDRS were averaged over the two assessment 
periods at baseline. Based on results of previous analyses (Freed et al., 2001; McRae et 
al., 2004) only scores from practically defined “off” periods were included in analyses. 
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Assessment periods included baseline, 12 and 24 months for both the real and sham 
surgery groups. The UPDRS can be found in Appendix B. 
Hoehn and Yahr Stage of Disease Scale 
The Hoehn and Yahr Stage of Disease Scale (Hoehn & Yahr, 1967) was 
administered to determine the stage of disease. This measure was filled out by patients 
and medical personnel at each assessment point during the study. Scores of the scale 
range from 0 (no signs of disease) to 5 (wheelchair bound or bedridden unless aided). 
Lower scores indicate fewer signs of disease. This scale is considered to be the standard 
disease staging scale for PD. McRae et al. (1994) found high interrater reliability between 
neurologists, patients, and caregivers with use of this scale. The Hoehn and Yahr Stage of 
Disease Scale can be found in Appendix C. 
Schwab and England Activities of Daily Living Scale 
Schwab and England Activities of Daily Living Scale was administered to assess 
ability to perform ADLs. This scale was designed specifically for use with PD patients 
and serves as a measure of overall functional ability regarding ADLs (Schwab & 
England, 1969). The scale ranges from 100% (completely independent) to 0% 
(bedridden), with each 10% increment having specific definitions. This scale is a 
common clinical measure of ADLs and has been used in many research studies with PD 
patients (Goetz et al., 1989; McRae et al., 1989). The Schwab and England Activities of 
Daily Living Scale can be found in Appendix D. 
Global Rating of Motor Functioning 
The Global Rating measure was designed and utilized as a primary outcome 
variable by Freed et al., (2001) in the original placebo surgery trial study. The measure 
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was utilized only at 12 months following the initial real or sham surgery to assess 
participant perception of clinical improvement or deterioration since the original surgery. 
The item requests that participants rate their current level of functioning on a scale 
ranging from -3 to +3, indicating they are markedly worse (-3) than before surgery, to no 
change (0), to markedly improved (+3) since surgery. The Global Rating Scale can be 
found in Appendix E.  
Quality of life 
Quality of life was originally examined as it related to three domains: Physical 
Functioning, Emotional Functioning, and Social Functioning. For purposes of this 
investigation, several representative scales from the Emotional and Social Functioning 
domains were included in the analyses. The selected scales are described below.  
 Center for Epidemiologic Studies Depression Scale (CES-D) 
 The Center for Epidemiologic Studies Depression Scale (CES-D) was used to 
assess depression, an aspect of emotional functioning. It is one of the most widely 
utilized rating scales to assess symptoms of depression (Hann, D., Winter, K., & 
Jacobsen, P., 1999); Radloff, 1977) The CES-D is a self-report scale consisting of 20 
items. The items are focused on emotions felt by respondents “in the past week” prior to 
filling out the measure.  Respondents choose from four response items: 1= Rarely or none 
of the time (Less than 1 day), 2= Some of the time/little of the time (1-2 days), 3= 
Occasionally or a Moderate Amount of the Time (3-4 days), 4= Most or All of the time 
(5-7 days). Total scores, which can range from 20 to 80, are then used to determine the 
level of depression experienced by the respondent.  Radloff (1977) reported reliability of 
the instrument to range between .85 and .90. In this study the coefficient alpha of the 
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CES-D at baseline was .89. The CES-D has a substantial research base to support its 
validity. The CES-D can be found in Appendix F.  
 Social Provisions Scale (SPS) 
 The Social Provisions Scale is a 24-item scale designed to measure the extent to 
which an individual’s current relationships provide the six social provisions described by 
Weiss (1974). The six provisions are: Attachment, Social Integration, Reassurance of 
Worth, Reliable Alliance, Guidance, and Opportunity for Nurturance. Half of the items 
describe the presence of a type of support and the others describe the absence of a type of 
support (Cutrona & Russell, 1987). Each item is rated on a 4-point scale ranging from 1 
(Strongly disagree) to 4 (Strongly agree). Cutrona and Russell (1987) reported reliability 
estimates ranged from .65 to .76 on the subscales measuring each of the social provisions. 
Cutrona and Russell (1987) also reported reliability of the total Social Provisions score to 
be .92.  Coefficient alpha of the Social Provisions Scale in this study was .91 at baseline. 
Validity of the instrument has been well established (Cutrona & Russell, 1987). The 
Social Provisions Scale can be found in Appendix G.  
Short-Form Health Survey 
 The Short-Form Health Survey (SF-36) is an instrument utilized to assess 
patients’ perceived health status (Ware & Sherbourne, 1992). The survey was derived 
from a large scale (n=20,000) study of medical outcomes. One global health item was 
utilized as a component of assessment in this study. This item asked patients “In general, 
how would you describe your health at present?” Patients responded to the item using a 
five-point Likert-type scale ranging from (1) “Excellent” to (5) “Poor.” 
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“Free or Restricted” Item 
 The Neural Implant Questionnaire was designed by McRae (2004) to capture 
patient and caregiver perspectives of the implications of PD on activity level. One item of 
this questionnaire is being used in this current study. The item asks participants “ Overall, 
how free or restricted do you feel in doing what you want to do?” Response options are 
presented with a 1 to 7 Likert-type scale with 1 being “I still do everything I want to do” 
to 7 being “I can no longer do the things I want to do.” Previous analyses of this single 
item have provided interesting and significant results (McRae et al., 2004).  
Additional focus  
In addition to comparing the transplant and sham surgery groups at baseline, 12 
and 24 months in regard to neuropsychological functioning, this study also analyzed 
neuropsychological ability based on perceived treatment at 12 months. Because previous 
results of analyses using perceived treatment groups have shown such extraordinary 
results, it was decided to explore neuropsychological data in the same way. Previous 
results have shown that comparisons of treatment groups based on type of surgery 
patients thought they received, showed more significant results both in terms of QOL 
data as well as medical data, than results based on actual treatment (McRae et al., 2004).  
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Data collection and research questions  
Stern and colleagues (Trott et al., 2003) collected the data in the original 
investigation and this study serves as a collaborative investigation between Dr. Stern’s 
group and this author.  
 Research questions relevant to this study are as follows: 
1) What are the relationships between neuropsychological functioning and QOL 
for real and sham surgery groups at baseline, 12, and 24 months post-surgery? 
2) What are the relationships between neuropsychological functioning and motor 
functioning for real and sham surgery groups at baseline, 12, and 24 months 
post-surgery? 
3) Are there any differences at baseline, 12, and 24 months between older (61+) 
and younger patients (<60) in the domain of neuropsychological functioning? 
4) Are there any differences at 12 months between those who thought they 
received the fetal cell transplant and those who thought they received the 
sham surgery in terms of neuropsychological functioning? 
Data analysis 
 Data were analyzed using SPSS. Preliminary analyses examining the 
neuropsychological measures were conducted. Analyses for the research questions 
included correlational analyses and analysis of variance (ANOVA).  
Correlational analyses were utilized to examine relationships between 
neuropsychological domains, motor functioning, and quality of life. Analysis of variance 
(ANOVA) was used to examine differences between older and younger participants and 
between those who thought they received the real and sham surgeries at 12 months.  
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Summary of Chapter III 
Chapter III outlined the methodology of the study in the areas of participants, 
procedures, and the measures used in assessing patient functioning in the domains of 
neuropsychological functioning, motor functioning, and quality of life. Results of these 
analyses will be reported in Chapter IV.   
 











 Chapter IV presents the results of the data analyses for this study. The chapter is 
organized by a) explaining the number of real and sham surgery patients at each data 
collection time point and b) results of preliminary analyses, and c) results of the research 
questions as they pertain to both the real and sham surgery groups at each data collection 
time point. Data for the real and sham surgery groups were analyzed separately to most 
accurately explore relationships and differences over time within the same groups.  
 This double-blind placebo surgery trial randomly assigned PD patients into real 
and sham surgery groups. However, at 12 months after the real surgery and after the blind 
was lifted, participants in the original sham group had the option to undergo the 
mesencephalic fetal cell transplant surgery. Due to the complex nature of this study and 
the tracking of participants, Table 2 was created to present the number of participants in 
the real and sham surgery groups at the different data collection time points.





Number of Real and Sham Surgery Participants at Each Data Collection Time Point 
 
 Real Changes to N Sham Changes to N 
Baseline N=20 ----------------- N=20 ----------------- 
12 Months N=19 -1 to death in 
car accident 
N= 20/ 
N= 12 had 2nd 
surgery 
-6 to age 
-1 to emotional 
distress at time of 
surgery 





----------------- ----------------- N=12 ----------------- 




----------------- ----------------- N=10 for 
Neuropsychological 
and QOL data 
N=4 for Motor 
Functioning * 
-1 because did not 
have data at 24 
months 
-1 to dementia 
* Due to the small number of sham surgery participants at 24 Months after the 2nd 
surgery, analyses regarding the relationship between neuropsychological and motor 
functioning were not completed. 
 
After the 12 month follow-up, several participants did not continue with the study. 
Six participants in the sham group were advised not to proceed due to their advanced age 
(being 61 or older). Another participant in the sham group chose not to have the 
transplant surgery because of family pressure not to have the surgery. One participant 
became overwhelmed in the operating room during the initial procedure and was not 
allowed to undergo a second attempt. One person who received the real surgery died in a 
car accident at seven months post-surgery. Therefore, data from a total of 31 patients 
were analyzed in the current study.  
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Preliminary analyses were conducted with the neuropsychological data to 
examine the mean and standard deviations of the measures over time in both the real and 
sham surgery groups. Results of the analyses for the real group are presented in Table 
2.1. Results for the Sham group are presented in Table 2.2. 
Table 2.1: Descriptive Statistics for Neuropsychological Measures Across Time for the 








    
 M (SD) M (SD) M (SD) 
    
COWAT 69.1 (29.39) 60.00 (38.00) 65.53 (32.34) 
BDAE: Animal 
Naming 
43.11 (33.60) 34.95 (30.77) 29.18 (32.50) 
WCST 4.84 (2.03) 4.81 (1.94) 4.47 (2.32) 
WAIS-R Digit 
Span Forward 
8.63 (2.31) 7.95 (2.60) 8.35 (2.32) 
WAIS-R Digit 
Span Backward 
7.32 (2.54) 7.47 (2.59) 7.18 (3.05) 
BVRT: 
Multiple-choice 
8.63 (1.77) 7.77 (2.02) 8.31 (1.58) 
BVRT: 
Matching 
9.53 (1.17) 9.11 (1.94) 9.62 (.50) 
CVLT 
Immediate 
51.58 (14.10) 48.44 (20.60)  
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Table 2.2: Descriptive Statistics for Neuropsychological Measures Across Time for the 














     
 M (SD) M (SD) M (SD) M (SD) 
     
COWAT 68.00 (26.17) 59.05 (31.34) 60.75 (30.65) 70.70 (27.84) 
BDAE: Animal 
Naming 
53.15 (26.42) 42.90 (29.69) 37.25 (22.59) 49.70 (33.33) 
WCST 5.67 (.77) 4.68 (2.38) 4.45 (2.84) 5.10 (1.52) 
WAIS-R Digit 
Span Forward 
9.40 (2.68) 8.45 (2.85) 9.33 (2.64) 9.10 (4.84) 
WAIS-R Digit 
Span Backward 
7.40 (3.14) 6.75 (2.15) 7.00 (2.45) 7.00 (3.83) 
BVRT: 
Multiple-choice 
8.70 (1.34) 8.20 (2.01) 8.83 (1.03) 8.90 (1.28) 
BVRT: 
Matching 
9.75 (.55) 9.50 (1.36) 9.58 (.67) 8.80 (3.12) 
CVLT 
Immediate 
49.70 (17.07) 50.83 (19.33)   
CVLT Delay 11.55 (3.80) 11.11 (3.21)   
 
Results and analyses will be presented in the same order as the research questions. 
Due to the small sample size and the exploratory nature of this study, the significance 
level was set at .10.  















What are the relationships between neuropsychological functioning and QOL for 
each group at baseline, 12, and 24 months post-surgery?  
SPSS was used to analyze data from measures across domains of 
neuropsychological functioning and aspects of QOL. Correlational analyses were used to 
examine relationships between measures of each type for the real and sham surgery 
groups at baseline, 12 and 24 months. Results are discussed as they pertain to each group 
at baseline, 12 and 24 months. The following results were found for the real group, or 
those who received the actual transplant surgery.  
There were no significant relationships at baseline (Table 3).  
At 12 months post-surgery, there were three significant relationships at the .05 
level and four at the .10 level (Table 3.1). The CES-D was related to four of the nine 
neuropsychological variables and Digit Span Backward was related to both the CES-D 
and the Free or Restricted item. Perceived social support was related to BDAE animal 
naming variable. 
At 24 months post-surgery for the real surgery group, significant relationships 
between neuropsychological functioning and QOL were found at both the .05 and .10 
levels. Four relationships were found to be significant at the .05 level and six 
relationships were found to be significant at the .10 level (Table 3.2). Perceived social 
support and the Free or Restricted item were both related to four of the seven 
neuropsychological variables, three of which they had in common; BDAE animal 
naming, WCST, and BVRT matching. BDAE animal naming was related to three of four 
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QOL domains while WCST, BVRT multiple-choice, and BVRT matching were related to 
two QOL variables each.  
 In summary, results for the real surgery group indicated that BDAE animal 
naming (verbal fluency) and BVRT multiple-choice and matching (visual memory) 
emerged as the neuropsychological measures most often correlated with aspects of QOL; 
significant relationships were found four and five times respectively. The CES-D was 
significantly related to five neuropsychological variables at 12 months, but only one at 24 
months. Conversely, the SPS and the Free or Restricted item were related to only one 
neuropsychological scale each at 12 months, but four scales each at 24 months.   
A summary table of significant relationships for the real surgery group at 






























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 












COWAT -.013 .051 .464 -.007 
BDAE: Animal 
Naming 
.464 -.217 .397 -.025 
Wisconsin Card 
Sort Test 
.371 -.456 .157 .263 
WAIS-R: Digit 
Span Forward 
-.077 .272 .252 -.034 
WAIS-R: Digit 
Span Backward 




.144 -.278 .133 .410 
BVRT: 
Matching 
.244 -.258 .215 -.207 
CVLT 
Immediate 
-.211 -.387 .272 -.140 



























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 












COWAT  -.023 .041 -.449 .082 
BDAE: Animal 
Naming 
.181 -.451 -.432 .640** 
Wisconsin Card 
Sort Test 
-.066 .072 -.590* .023 
WAIS-R: Digit 
Span Forward 
.166 -.164 -.374 .283 
WAIS-R: Digit 
Span Backward 




-083 -.039 -.684** -.154 
BVRT: 
Matching 
.041 .183 -.177 -.153 
CVLT: 
Immediate 
-.217 .028 -.592* .267 
CVLT: Delay -.396 .397 -.580* .241 
 
* p < .10 
























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 












COWAT -.411 -.450 -.024 .399 
BDAE: Animal 
Naming 
-.709** -.586* -.111 .757** 
Wisconsin Card 
Sort Test 
.026 -.616* -.564 .683* 
WAIS-R: Digit 
Span Forward 
-.208 -.368 -.368 .616* 
WAIS-R: Digit 
Span Backward 




-.176 -.674** -.579 .638* 
BVRT: 
Matching 
-.527 -.666** -.616* .419 
CVLT 
Immediate 
    
CVLT Delay     
 
* p < .10 
** p < .05 





Question 1: Significant Correlations Between Neuropsychological Functioning and 
Quality of Life Across Time for the Real Surgery Group  
 
 Scale Names Specific Domains Correlation  
p <.05 
Correlation 
p < .10 
Baseline     
     
12 Months     
 BDAE: Animal Naming & 
SPS 
Verbal Fluency & Social Support .640  
 WCST & CES-D Executive Functioning & 
Depression 
 -.590 
 WAIS-R: Digit Span 
Backward & Free or 
Restricted 
Working Memory & Effect of PD 
on Activity Level 
 -.558 
 WAIS-R: Digit Span 
Backward & CES-D 
Working Memory & Depression -.608  
 BVRT: Multiple-choice & 
CES-D 
Visual Memory & Depression -.684  
 CVLT: Immediate &  
CES-D 
Learning and Verbal Memory & 
Depression 
 .592 
 CVLT: Delay & 
CES-D 
Learning and Verbal Memory & 
Depression 
 .580 
24 Months     
 BDAE: Animal Naming & 
SF-36  
Verbal Fluency & Perceived 
Health at Present 
-.709  
 BDAE: Animal Naming & 
Free or Restricted 
Verbal Fluency & Effect of PD on 
Activity Level 
 -.586 
 BDAE: Animal Naming & 
SPS 
Verbal Fluency & Social Support .757  
 WCST & Free or 
Restricted 
Executive Functioning & Effect of 
PD on Activity Level 
 .616 
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Table 3.3: Continued 
 
Question 1: Significant Correlations Between Neuropsychological Functioning and 





    
 WCST & SPS Executive Functioning & Social 
Support 
 .683 
 WAIS-R: Digit Span 
Forward & SPS 
Immediate Verbal Memory & 
Social Support 
 .616 
 BVRT: Multiple-choice & 
Free or Restricted 
Visuospaital Capabilities & Effect 
of PD on Activity Level 
-.674  
 BVRT: Multiple-choice & 
SPS 
Visual Memory & Social Support  .638 
 BVRT: Matching & Free 
or Restricted 
Visual Memory & Effect of PD on 
Activity Level 
-.666  
 BVRT: Matching &  
CES-D 
Visual Memory & Depression  -.616 
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Results of correlational analyses for the sham surgery group also resulted in 
significant relationships between a number of neuropsychological and QOL measures, 
although there were fewer overall than in the real surgery group.  
At baseline, there was one significant correlation at the .05 level and three 
significant correlations at the .10 level (Table 3.4). Results indicated that BVRT 
matching was related to two measures of QOL (CES-D and Free or Restricted) while the 
Free or Restricted item was correlated with two neuropsychological measures (COWAT 
and BVRT matching).  
At 12 months after sham surgery, before the double-blind was lifted, there were 
two significant relationships at the .05 level and one significant relationship at the .10 
level (Table 3.5). The WCST was related to both the CES-D and SPS. Among the four 
QOL instruments, the SPS was related to two of the nine neuropsychological instruments.  
When the blind was lifted for the patients who initially received the sham surgery, 
12 patients elected to have the real transplant surgery. At 12 months post-real surgery for 
the sham group, one relationship was found to be significant at the .05 level and one at 
the .10 level (Table 3.6).  WAIS-R Digit Span Backward was related to the SF-36 (1 
item) and BVRT multiple-choice was related to the SPS.  
Finally, at 24 months post-real surgery for the sham surgery group, one significant 
relationship was found between BVRT matching and the SPS (Table 3.7).  
Overall results of the sham surgery group at baseline, 12 months post-sham 
surgery, and 12 and 24 months post-real surgery indicated that the BVRT matching 
(visual memory) was the neuropsychological measure most often correlated with QOL 
measures (three times). BVRT matching correlated with the Free or Restricted item, the 
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CES-D (depression), and with the SPS (social support). The SPS was the QOL measure 
most often correlated with neuropsychological measures (5 times). The SPS correlated 
twice with CVLT delay (learning and verbal memory), and once with WCST (executive 
functioning), BVRT multiple-choice and BVRT matching (visual memory). All of the 
significant relationships for the sham surgery group at baseline, 12 months post-sham 








































Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 












COWAT -.267 .461* .245 .085 
BDAE: Animal 
Naming 
-.159 .240 .212 -.040 
Wisconsin Card 
Sort Test 
-.367 .170 -.006 .295 
WAIS-R: Digit 
Span Forward 
-.038 .316 .059 -.011 
WAIS-R: Digit 
Span Backward 




.024 -.061 -.136 .164 
BVRT: 
Matching 
.019 -.437* -.600** .413 
CVLT 
Immediate 
.000 .239 -.166 .328 
CVLT Delay -.110 .119 -.053 .445* 
 
* p < .10 
























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 












COWAT -.341 .101 -.162 .255 
BDAE: Animal 
Naming 
-.380 .372 .171 .098 
Wisconsin Card 
Sort Test 
.121 -.134 -.520** .476* 
WAIS-R: Digit 
Span Forward 
.000 -.081 -.102 .132 
WAIS-R: Digit 
Span Backward 
-.246 .070 .144 .159 
BVRT: 
Multiple-choice 
.068 .030 .002 .068 
BVRT: 
Matching 
.116 -.041 -.123 .008 
CVLT 
Immediate 
-.042 .354 .134 .145 
CVLT Delay .144 .160 -.233 .538** 
 
* p < .10 

























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 
Sham Surgery Group at 12 Months after 2nd Surgery 
 
 
12 Months after 
2nd Surgery  








COWAT -.440 -.236 -.147 -.038 
BDAE: Animal 
Naming 
-.521 .362 .241 -.055 
Wisconsin Card 
Sort Test 
-.080 -.363 .274 -.286 
WAIS-R: Digit 
Span Forward 
-.495 -.233 -.092 -.452 
WAIS-R: Digit 
Span Backward 
-.699** .299 .134 -.250 
BVRT: 
Multiple-choice 
-.167 .000 .311 -.610* 
BVRT: 
Matching 
-.225 .527 .096 -.242 
 
* p < .10 




























Question 1: All Correlations for Neuropsychological and Quality of Life Measures for the 
Sham Surgery Group at 24 Months after 2nd Surgery 
 
 
24 Months after 
2nd Surgery  








COWAT -.291 .431 -.124 -.390 
BDAE: Animal 
Naming 
-.142 .061 .053 -.382 
Wisconsin Card 
Sort Test 
.483 .427 .453 -.206 
WAIS-R: Digit 
Span Forward 
-.365 .456 .230 -.146 
WAIS-R: Digit 
Span Backward 
-.426 .260 -.048 -.048 
BVRT: 
Multiple-choice 
.175 -.228 .469 -.519 
BVRT: 
Matching 
-.181 .145 .275 -.768** 
 
** p < .05 





Question 1: Significant Correlations Between Neuropsychological Functioning and 
Quality of Life Across Time for the Sham Surgery Group  




Baseline     




and Effect of PD 






Visual Memory & 






Visual Memory & 
Depression 
-.600  
 CVLT Delay & 
SPS 
Learning and 
Verbal Memory & 
Social Support 
 .445 
12 Months     
 Wisconsin Card 






 Wisconsin Card 






 CVLT Delay & 
SPS 
Learning & 
Verbal Memory & 
Social Support 
.538  
12 Months after 
2nd Surgery 
    
 WAIS-R: Digit 
Span Backward 










Visual Memory & 
Social Support 
 -.610 
24 Months after 
2nd Surgery 




Visual Memory & 
Social Support 
-.768  




What are the relationships between neuropsychological functioning and motor 
functioning for each group at baseline, 12, and 24 months post-surgery? 
Several significant relationships were found for the real surgery group at baseline.  
Four relationships were significant at the .01 level, five were found to be significant at 
the .05 level, and four were significant at the .10 level (Table 3.9).  
Analysis of baseline data revealed that the four relationships found at the .01 level 
were between BVRT matching and all four motor functioning measures; Hoehn and 
Yahr, Schwab and England, UPDRS total, and UPDRS Motor “off.  
At the .05 level, BVRT multiple-choice was correlated with the same four motor 
functioning measures. Relationships at the .10 level were not consistent across measures. 
Thus, BVRT multiple-choice and matching were strikingly consistent in terms of their 
relationships with motor functioning measures at baseline.  
 





Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 














































-.497** .462** -.463** -.507** 
BVRT: 
Matching 
-.624*** .603*** -.580*** -.578*** 
CVLT 
Immediate 
-.209 .103 -.410* -.374 
CVLT Delay -.362 .278 -.482** -.427* 
*p < .10 
**p < .05 
*** p < .01 
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        Analyses for the real surgery group at 12 months resulted in three significant 
relationships at the .05 and six significant relationships at the .10 level between 
neuropsychological functioning and motor functioning measures (Table 4). The most 
notable result was that the Hoehn and Yahr, a measure of disease severity, was related to 










































Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 





















COWAT -.430* .282 -.257 -.256 .151 
BDAE: Animal 
Naming 
-.294 .328 -.283 -.324 .200 
Wisconsin Card 
Sort Test 
-.368 .218 -.145 -.116 .157 
WAIS-R: Digit 
Span Forward 
-.408* .182 -.222 -.276 -.115 
WAIS-R: Digit 
Span Backward 
-.418* .272 -.359 -.404* -.037 
BVRT:Multiple- 
choice 
-.562** .422* -.366 -.287 .088 
BVRT: 
Matching 
-.553** .499** -.272 -.231 .292 
CVLT 
Immediate 
-.429* .278 -.223 -.258 .243 
CVLT Delay -.369 .198 -.148 -.183 .017 
*p < .10 
**p < .05 
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Data analyses for the real group at 24 months resulted in three significant 
relationships at the .05 level and one at the .10 level (Table 4.1). The UPDRS total score 
was the measure of motor functioning most often correlated with neuropsychological 
instruments (two times), having significant relationships with WCST and BVRT 
multiple-choice.   
Overall results of correlational analyses for the real surgery group at baseline, 12  
and 24 months indicated that BVRT multiple-choice and matching (visual memory), were 
the measures of neuropsychological functioning that most often and powerfully 
correlated with motor functioning measures. The Hoehn and Yahr Stage of Disease Scale 
was the motor functioning measure most often correlated with neuropsychological 
functioning measures. Results of significant relationships for the real surgery group at 



















Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 
for the Real Surgery Group at 24 Months 
 
 




























-.330 .320 -.620** -.132 
BVRT: 
Matching 
-.009 .024 -.168 -.084 
*p < .10 
**p < .05 
 





Question 2: Significant Correlations Between Neuropsychological Functioning and 





 Scale Names Specific Domains Correlation 
p < .01 
Correlation  
p < .05 
Correlation 
p < .10 
Baseline      
 BDAE: Animal 
Naming & Schwab 
and England 
Verbal Fluency & Activities 
of Daily Living 
  .391 
 WCST & UPDRS 
Total 
Executive Functioning & 
Severity of Illness 
  -.404 
 BVRT: Multiple-
choice & Hoehn and 
Yahr 
Visual Memory & Severity 
of Illness 
 -.497  
 BVRT: Multiple-
choice & Schwab and 
England 
Visual Memory & Activities 
of Daily Living 
 .462  
 BVRT: Multiple-
choice & UPDRS 
Total 
Visual Memory & Severity 
of Illness 
 -.463  
 BVRT: Multiple-
choice & UPDRS 
Motor “off” 
Visual Memory & Severity 
of Illness Off of Medication 
 -.507  
 BVRT: Matching & 
Hoehn and Yahr 
Visual Memory & Stage of 
Disease 
-.624   
 BVRT: Matching & 
Schwab and England 
Visual Memory & Activities 
of Daily Living 
.603   
 BVRT: Matching & 
UPDRS Total 
Visual Memory & Severity 
of Illness 
-.580   
 BVRT: Matching & 
UPDRS Motor “off” 
Visual Memory & Severity 
of Illness Off of Medication 
-.578   
 CVLT Immediate & 
UPDRS Total 
Learning and Verbal 
Memory & Severity of 
Illness 
  -.410 
 CVLT Delay & 
UPDRS Total 
Learning and Verbal 
Memory & Severity of 
Illness 
 -.482  
 CVLT Delay & 
UPDRS Motor “off” 
Learning and Verbal 
Memory & Severity of 
Illness Off of Medication 
  -.427 
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Table 4.2: Continued 
 
Question 2: Significant Correlations Between Neuropsychological Functioning and 
Motor Functioning Across Time for the Real Surgery Group  
 
 
 Scale Names Specific Domains Correlation 
p < .01 
Correlation  
p < .05 
Correlation 
p < .10 
12 
Months 
     
 COWAT & Hoehn and 
Yahr 
Verbal Fluency &  
Stage of disease 
  -.430 
 WAIS-R: Digit Span 
Forward & Hoehn and 
Yahr 
Working Memory &  
Stage of disease 
  -.408 
 WAIS-R: Digit Span 
Backward & Hoehn 
and Yahr 
Working Memory &  
Stage of disease 
  -.418 
 WAIS-R: Digit Span 
Backward & UPDRS 
Motor “off” 
Working Memory & 
Severity of Illness Off of 
Medication 
  -.404 
 BVRT: Multiple-
choice & Hoehn and 
Yahr 
Visual Memory &  
Stage of disease 
 -.562  
 BVRT: Multiple-
choice & Schwab and 
England 
Visual Memory & Activities 
of Daily Living 
  .422 
 BVRT: Matching & 
Hoehn and Yahr 
Visual Memory &  
Stage of disease 
 -.553  
 BVRT: Matching & 
Schwab and England 
Visual Memory & Activities 
of Daily Living 
 .499  
 CVLT Immediate & 
Hoehn and Yahr 
Immediate Verbal Memory 
& Stage of disease 
  -.429 
24 
Months 
     
 COWAT & Hoehn and 
Yahr 
Verbal Fluency &  
Stage of disease 
  -.518 
 BDAE: Animal 
Naming & Schwab and 
England 
Verbal Fluency & Activities 
of Daily Living 
  .535 
 WCST & UPDRS 
Total 
Executive Functioning & 
Severity of Illness 
  -.575 
 BVRT: Multiple-
choice & UPDRS Total 
Visual Memory & Severity 
of Illness 
 -.620  
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Results of data analyses for the sham surgery group at baseline, 12 months post- 
sham surgery, and 12 months post-real surgery varied greatly from the real surgery 
group. As stated previously, due to the small number of patients for whom we have 
neurological (motor) data at 24 months post-real surgery, analyses at this data point were 
excluded. 
At baseline, no significant results were found (Table 4.3). Two relationships were 
significant at 12 months post-sham surgery (Table 4.4).  
At 12 months post-real surgery for the sham surgery group, BDAE animal naming 
was related with all four of the motor functioning instruments (Table 4.5).  
 In summary, for the sham surgery group at baseline, 12 months post-sham  
surgery, and 12 months post-real surgery, BDAE animal naming and BVRT matching 
were the neuropsychological measures that correlated most frequently with motor 
functioning measures.  
A summary of significant relationships for the sham surgery group at baseline, 12 
months post-sham surgery and 12 months post-real surgery is presented in Table 4.6.  
Overall results of correlational analyses for both real and sham surgery groups 
across time points indicated that BVRT multiple-choice and matching (visual memory) 
and BDAE animal naming (verbal fluency) were the measures of neuropsychological 
functioning that most often correlated with motor functioning measures. The Hoehn and 
Yahr Stage of Disease Scale was the motor functioning measure most notably correlated 










Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 
for the Sham Surgery Group at Baseline 
 
 
Baseline Hoehn & Yahr Schwab & 
England 
UPDRS Total UPDRS: 
Motor “off” 




-.283 .253 -.233 -.205 
Wisconsin 
Card Sort Test 












-.271 .263 -.343 -.258 
BVRT: 
Matching 
.047 .060 -.187 -.169 
CVLT 
Immediate 
-.170 .152 -.081 .021 
CVLT Delay -.180 .026 -.169 -.083 





Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 
for the Sham Surgery Group at 12 Months 
 





























.061 -.277 -.366 -.301 -.041 
BVRT: 
Matching 
.185 -.214 -.133 -.012 -.198 
CVLT 
Immediate 
.079 -.219 -.015 -.012 .319 
CVLT Delay .069 -.179 .026 .077 .432* 
*p < .10 
**p < .05 
 





Question 2: All Correlations for Neuropsychological and Motor Functioning Measures 

































.467 -.611** .292 .202 
BVRT: 
Matching 
.050 -.312 -.067 -.080 
*p < .10 
**p < .05 
***p < .01 
 





Question 2: Significant Correlations Between Neuropsychological Functioning and  









 Scale Names Specific Domains Correlation  
p < .01 
Correlation  
p < .05 
Correlation 
p < .10 
Baseline      
      
12 Months      
 WCST & Schwab and 
England 
Executive Functioning & 
Activities of Daily Living 
 -.543  
 CVLT Delay & Global 
Rating of Functioning 
Learning and Verbal 
Memory & Perceived 
Functioning 




     
 BDAE: Animal Naming 
& Hoehn and Yahr 
Verbal Fluency & Stage of 
disease 
  .557 
 BDAE: Animal Naming 
& Schwab and England 
Verbal Fluency & Activities 
of Daily Living 
  -.535 
 BDAE: Animal Naming 
& UPDRS Total 
Verbal Fluency & Severity 
of Illness 
 .064  
 BDAE: Animal Naming 
& UPDRS Motor “off” 
Verbal Fluency & Severity 
of Illness Off of Medication 
.731   
 BVRT: Multiple-choice 
& Schwab and England 
Visual Memory & Activities 
of Daily Living 
 -.611  




Are there any differences at baseline, 12, and 24 months between older (61+) and  
younger patients (<60) in the domain of neuropsychological functioning for each group? 
 Analysis of variance (ANOVA) was used to examine differences between age 
groups with respect to neuropsychological functioning at each time point. Results are 
presented for real and sham surgery groups at baseline, 12, and 24 months.  
Results of analyses for the real surgery group showed several differences between 
younger and older participants at each time point (Table 4.8). Younger participants 
performed better than older participants in each instance.  
Results of analyses for the sham surgery group showed differences only at 
baseline, perhaps because of extremely small sample sizes in the older group, three and 
one respectively for 12 and 24 months after real surgery. Younger participants performed 
better than older participants on BDAE animal naming (verbal fluency), BVRT multiple-
choice (visual memory), and CVLT delay (learning and verbal memory; Table 4.9).  
In summary, differences were seen between younger and older participants in the 
real surgery and sham surgery groups over time. The majority of the differences were on 
measures of verbal fluency and verbal memory. In all cases, younger participants 
















Question 3: Differences Between Older and Younger Participants on Measures of 
Neuropsychological Functioning at Baseline, 12 and 24 Months for the Real Surgery 
Group 
 





Baseline      
COWAT Between 





12564.889 17 739.111 
 









Groups 15767.156 17 927.480 
 
 Total 20325.789 18   
      
12 Months      
COWAT Between 
Groups 





20790.322 17 1222.960 
 
 Total 25994.000 18   
WCST Between 
Groups 11.358 1 11.358 3.52* 
 Within 
Groups 
45.079 14 3.220 
 
 Total 56.437 15   
 
* p < .10 
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Table 4.7: Continued 
 
Question 3: Differences Between Older and Younger Participants on Measures of  



















* p < .10 
** p < .05 
  
































 Total 37.438 15   





Question 3: Differences Between Older and Younger Participants on Measures of 
Neuropsychological Functioning at Baseline for the Sham Surgery Group 
 










2034.368 1 2034.368 3.26* 
 Within 
Groups 11230.182 18 623.899 
 




Groups 10.766 1 10.766 8.27*** 
 Within 
Groups 
23.434 18 1.302 
 
 Total 34.200 19   
CVLT Delay Between 
Groups 
65.091 1 65.091 5.58** 
 Within 
Groups 209.859 18 11.659 
 
 Total 274.950 19   
 
* p < .10 
** p < .05 
*** p < .01 




Are there any differences at 12 months between those who thought they received   
the fetal cell transplant and those who thought they received the sham surgery in the 
domain of neuropsychological functioning? 
This question was addressed because of the significant results that were found in 
previous analyses with these data based on perceived groups, or those who thought they 
received the real or sham surgery. Analysis of variance (ANOVA) was used to examine 
differences between groups with respect to neuropsychological functioning one year after 
surgery, before the blind was lifted. No differences were found between those who 
thought they received the mesencaphalic fetal cell transplant and those who thought they 
received the sham surgery one year after the initial surgery.  
 In summary, this chapter reported results of the preliminary analyses and the 
research questions. Many significant, although rather inconsistent, relationships were 
found between neuropsychological, motor, and quality of life variables. There were some 
differences based on age, with younger patients achieving better results on 
neuropsychological testing than older patients. There were no significant differences 
found between perceived real and sham surgery groups on neuropsychological testing 12 













The original study by Stern and colleagues (Trott et al., 2003) evaluated 
neuropsychological differences between the real and sham surgery groups 12 months 
following the double-blind sham surgery procedure. Because data were collected for 
participants up to 24 months and beyond, this study was undertaken to investigate the 
long-term effects of the transplant on both the original transplant group as well as those 
who had the sham surgery first and then received the transplant. Although the primary 
focus of the study was on neuropsychological results, another aim of the study was to 
examine relationships between neuropsychological functioning, motor functioning, and 
quality of life.  
Preliminary Analyses 
Preliminary analyses of neuropsychological measures were conducted for both 
groups to assess for central tendency and comparability of results over time (see Tables 
2.1 and 2.2). Although significance testing was not done to compare means across data 
collection points because of the small sample size, results will be discussed briefly. 
Because of the uniqueness of the sample and the study, and because of the exploratory 
nature of the investigation, this non-traditional approach to discussing non-significant 
results is being taken. Results that are even suggestive of possible fruitful avenues of 
further research have been sanctioned by the organization that funded this project, the 
National Institute of Neurological Disorders and Stroke.  
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Results of preliminary analyses for the real surgery group showed decline in mean 
scores on eight of the nine neuropsychological measures from baseline to 12 months. 
However, there were increases in mean scores on four of the seven neuropsychological 
measures from 12 to 24 months (only seven measures were administered at 24 months). 
These increases were seen on tests of verbal fluency, immediate verbal memory, and 
visual memory. This result seems rather unusual since the typical trajectory of 
neuropsychological functioning in PD is downward, indicating that patients get worse 
over time. 
There are several potential explanations for these findings. First, two participants 
in the real surgery group became demented and were withdrawn from the study. 
Exclusion of data from these two participants at 24 months undoubtedly affected the 
means of the total scores for the remaining group. Second, increases in mean scores may 
be suggestive of beneficial treatment effects from the transplant surgery in terms of 
neuropsychological functioning.  
Results of preliminary analyses for the sham surgery group showed decline on 
eight of the nine neuropsychological measures from baseline to 12 months. The scales 
that showed an increase were not the same for the real and sham groups. From 12 to 24 
months after the second surgery, mean scores increased on four of the seven 
neuropsychological measures and remained the same for one measure. These increases 
were seen on tests of verbal fluency, executive functioning, and visual memory while 
WAIS-R Digit Span Backward, a test of working memory, remained constant. Increases 
from 12 to 24 months post-transplant were found in both real and sham groups on 
COWAT and BVRT multiple-choice. It is interesting to observe that mean scores for the 
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10 patients in the sham group at 24 months following the second surgery were, in most 
cases, greater than scores of the 20 participants at 12 months and greater than or equal to 
scores of 12 participants at 12 months after the second surgery.  
Much like the real group, exclusion of six participants aged 61 and older 12 
months after the initial sham surgery may explain some of the improvement in scores 
following the second surgery as it left mostly younger participants in the study. In 
addition, one participant in this group was withdrawn due to dementia and exclusion of 
these data in all probability also influenced remaining scores. At 24 months following the 
second surgery there were only 10 participants in the sham to transplant group, 
apparently comprised of the younger and more able participants whose scores were 
perhaps higher than those who dropped out of the study. Another explanation of these 
results may be that improvement was seen after fetal cell transplant surgery. Even 
relatively stable scores over the period of at least three years in this group is remarkable 
at such advanced stages of disease. 
Overall, scores for both groups appeared to benefit from exclusion of data of 
demented and older participants. However, it is important to explore the possibility that 
the relative stability of some scores was related to the positive effects of the fetal cell 
transplant surgery.  
Question 1 
Correlational analyses of the relationships between neuropsychological 
functioning and QOL yielded several findings. With respect to the real surgery group, the 
CES-D, a measure of depression, emerged as a variable that related significantly to 
several neuropsychological variables at 12 months. Higher depression was related to 
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lower neuropsychological scores. Depression is known to interrupt attention and 
concentration and may explain these relationships.  
Perceived social support and the Free or Restricted item were both related to 
several neuropsychological variables at 24 months. Relationships between the SPS and 
neuropsychological variables were all positive, indicating that more social support was 
related to better scores. Relationships between the Free or Restricted scores and 
neuropsychological variables were all negative. However, because of the scaling of the 
Free or Restricted item, more “freedom” to do what the patient would like to do was 
related to higher neuropsychological scores.  
The fact that the most salient QOL variables changed from the CES-D at 12 
months to SPS and Free or Restricted at 24 months may indicate that social support and 
freedom, or independence may be more valued or desired by participants at 24 months 
than at baseline and 12 months. This change may also be suggestive of a tendency for 
participants to transition from primarily individual and internal coping methods to group 
and external coping methods. 
No one neuropsychological test stood out as a correlate with QOL at 12 months 
post-surgery, suggesting equal performance across domains. Correlations between the 
WCST, BVRT multiple-choice, and BVRT matching were evenly distributed; relating 
two times with QOL measures at 24 months post-surgery (see Table 3.2). The most 
consistent findings at 24 months were the relationships between BDAE animal naming 
and three of the QOL variables. These results suggest that verbal fluency and visual 
memory were clearly related to QOL. 
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With respect to the sham surgery group, there were fewer significant relationships 
between neuropsychological and QOL measures over time than in the real surgery group. 
Aside from baseline, when results for the sham surgery group showed more significant 
correlations than the real surgery group, there were no consistent results across 
assessment points. This result may be related to a diminishing sample size that began 
with 20 at baseline and decreased to 10 by 24 months.  
Overall results for the sham surgery group indicated that the WCST and BVRT 
matching were the neuropsychological measures most often correlated with QOL 
measures. This is consistent with findings for the real surgery group, suggesting that 
impairments in executive functioning and visual memory significantly impact QOL. 
Social support was the QOL measure most often correlated with neuropsychological 
measures, which was also found in the real surgery group. 
Overall, for both groups, results were fairly equally distributed among three scales 
in their relationships with QOL variables: BDAE animal naming (four times), BVRT 
multiple-choice (four times), and BVRT matching (six times). Two QOL measures stood 
out in their relationships with neuropsychological measures. Social support was the 
aspect of QOL that was most consistently (10 times) correlated with neuropsychological 
measures for both groups over time. Results indicated each time that more support was 
related to better neuropsychological results. Depression was related to 
neuropsychological results eight times across groups and assessment points, with more 
depression related to lower neuropsychological scores.  
 
 




Analysis of the relationships between neuropsychological and neurological 
functioning for the real surgery group resulted in several significant findings. BVRT 
multiple-choice and BVRT matching were strongly related to neurological functioning at 
baseline, with better neuropsychological results linked with better neurological 
functioning. BVRT matching obtained significance with motor measures at the .01 level, 
which is particularly powerful when considering the small sample size in this study. 
These results indicate that BVRT matching, a measure of visual memory, was 
significantly related to stage of disease, participation in activities of daily living, severity 
of illness, and motor functioning when off medication. BVRT multiple-choice was 
consistently related to all four neurological measures at the .05 level. These relationships 
highlight the apparently parallel declines in visual memory and functioning related to PD 
experienced by these participants.  
UPDRS Total and Motor “off” were both related to neuropsychological measures 
for the real surgery group at baseline. These results indicate that severity of symptoms 
and performance on neuropsychological measures were linked before surgery. However, 
results also raise the question of what happened to these relationships at 12 and 24 
months. It may be that sample size, which changed from 20 to 19 to 17 over the period of 
study, affected the results. It is also possible that relationships among the variables were 
changing because of effects of the surgery.  
A similar result was found at 12 months when the Hoehn and Yahr Stage of 
Disease Scale correlated significantly with the majority of neuropsychological 
functioning measures. These results also show the link between neuropsychological 
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functioning and severity of illness, or stage of disease. Why this should be so apparent at 
12 months and not at baseline and 24 months is difficult to determine with these data. 
Overall, BVRT multiple-choice and BVRT matching, measures of visual 
memory, were the neuropsychological functioning measures that were most strongly 
correlated with motor functioning measures. The Hoehn and Yahr (nine times) and the 
UPDRS Total (eight times) were the motor functioning measures most often correlated 
with neuropsychological functioning measures.  
Results of analyses of relationships between neuropsychological and neurological 
functioning in the sham surgery group are remarkable because of their lack of 
significance. There were no significant relationships at baseline, only two at 12 months, 
and eight at 12 months after the transplant surgery.  
Among the results 12 months after the real surgery for the sham group, BDAE 
animal naming, a verbal fluency measure, correlated with all four measures of 
neurological functioning. This result was surprising because it was not found at baseline 
and 12 months after initial surgery, nor was it found in the real group at any time. The 
directionality of the relationships are all as expected, with higher neuropsychological 
scores related to better physical functioning. Keeping in mind that this was a refined 
group of 12 mostly “younger” participants, it is possible that the animal naming measure 
was particularly sensitive to the changes resulting from the transplant surgery.  
Question 3 
Younger participants performed better than older participants on several measures 
across time points in both the real and sham surgery groups. Of the five differences in the 
real group, four were related to verbal fluency (see Table 4.8). In the sham group one of 
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three differences was a measure of verbal fluency (see Table 4.9). Two differences (one 
in both real and sham groups) were found in BVRT multiple-choice, or a measure of 
visual memory. These differences may be explained by the fact that younger persons 
typically perform better than older persons on measures of neuropsychological 
functioning. However, it is noteworthy that such compelling results were found regarding 
verbal fluency.  
Question 4 
No differences were found between those who thought they received the fetal cell 
transplant and those who thought they received the sham surgery on measures of 
neuropsychological functioning. While previous research has shown that the placebo 
effect influenced ratings of perceived health and QOL among patients and medical 
personnel, this effect apparently did not extend to neuropsychological test performance. 
Although it might have been conceivable for the placebo effect to influence measures of 
attention, (e.g., belief that treatment was received may have increased attention whereas 
belief that treatment was not received may have decreased attention), it would have been 
unusual for it to have influenced overall performance. Results of analyses for this 
question indicated there were no differences between groups. 
Strengths of the Study 
A major strength of this unique study was the opportunity to evaluate longitudinal 
data of PD patients who participated in a double-blind placebo surgery trial. The original 
study was complex, and data were collected to capture performance in multiple domains 
over an extended period of time. The opportunity to analyze longitudinal data is often 
regarded as a privilege since it allows researchers to consider what happens in various 
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domains over time. In the realm of this very experimental and esoteric study, this is 
especially true. The neuropsychological data had only been examined to 12 months and 
the sample was only regarded as a whole, not two separate groups (real and sham), with 
possibly two rather different profiles of relationships and change over time. This study 
allowed for examination of neuropsychological data up to 24 months after surgery and 
explored reasons for some of the interesting results, including the possibility that the 
transplant had some effect on the neuropsychological results.  
Limitations of the Study 
There are several limitations of this study that must be considered. The most 
obvious is that the sample size was very small, even at baseline. Because archival data 
were used in this study, there was no way to remedy this difficulty. It is interesting to 
note that the dilemma of sample size was only magnified over time as participants 
dropped out of the study because of age or were removed because of dementia. In spite of 
the small number of participants, there were a remarkable number of significant 
differences and correlations. 
Another limitation specific to this study is that the number of analyses that were 
conducted increased the possibility of Type I error. Unfortunately, because of the 
research questions, this approach was unavoidable.  
For reasons unknown to the author, the CVLT was not given at each time point 
for each group. Thus, results of this study cannot be considered to be conclusive over 
time with respect to this measure of learning and verbal memory. The impact of the data 
that may have been collected at later time points on this measure is unknown.  
 




Observations regarding several sets of analyses suggested that changes related to 
the fetal cell transplant surgery may have been one possible explanation for the results. 
While further exploration of these data may provide some additional information, a 
follow-up study with another fetal transplant surgery group will probably not be done to 
extend and investigate these results in more depth. 
Results gave some support to relationships that have been reported in other 
investigations (e.g., depression and neuropsychological performance). Further 
exploration of other relationships found in this study (e.g., the relationships between 
social support and neuropsychological performance) with other samples might be a 
helpful direction to take for future research.  
Finally, it was interesting to observe the development of differences in 
neuropsychological functioning over time. This result has implications for continuing to 
test patients receiving other types of surgical interventions for PD such deep brain 
stimulation. Changes in functioning may take much longer than previously thought, with 
changes occurring up to 24 months and possibly beyond. In order to really capture 
differences, it is recommended that control groups of matched patients be tested along 
with the experimental patients in any intervention in order to consider the normal 
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Unified Parkinson Disease Rating Scale (UPDRS) 
I.  Mentation, Behavior, Mood  
       
    Intellectual Impairment  
       0-none 
       1-mild (consistent forgetfulness with partial recollection of events with no other  
difficulties) 
       2-moderate memory loss with disorientation and moderate difficulty handling  
complex problems 
       3-severe memory loss with disorientation to time and often place, severe impairment  
with problems 
       4-severe memory loss with orientation only to person, unable to make judgments or  
solve problems 
     
    Thought Disorder  
       0-none 
       1-vivid dreaming 
       2-"benign" hallucination with insight retained 
       3-occasional to frequent hallucination or delusions without insight, could interfere  
with daily activities 
       4-persistent hallucination, delusions, or florid psychosis. 
 
     Depression 
       0-not present 
       1-periods of sadness or guilt greater than normal, never sustained for more than a few  
days or a week 
       2-sustained depression for >1 week 
       3-vegetative symptoms (insomnia, anorexia, abulia, weight loss) 
       4-vegetative symptoms with suicidality 
 
     Motivation/Initiative 
       0-normal 
       1-less of assertive, more passive 
       2-loss of initiative or disinterest in elective activities 
       3-loss of initiative or disinterest in day to say (routine) activities 
       4-withdrawn, complete loss of motivation 
 
II. Activities of Daily Living  
     Speech 
       0-normal 
       1-mildly affected, no difficulty being understood 
       2-moderately affected, may be asked to repeat 
       3-severely affected, frequently asked to repeat  
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       4-unintelligible most of time 
 
     Salivation 
       0-normal 
       1-slight but noticeable increase, may have nighttime drooling 
       2-moderately excessive saliva, hay minimal drooling 
       3-marked drooling 
 
     Swallowing 
       0-normal 
       1-rare choking 
       2-occasional choking 
       3-requires soft food 
       4-requires NG tube or G-tube 
 
     Handwriting 
       0-normal 
       1-slightly small or slow 
       2-all words small but legible 
       3-severely affected, not all words legible 
       4-majority illegible 
 
     Cutting Food/Handing Utensils 
       0-normal 
       1-somewhat slow and clumsy but no help needed 
       2-can cut most foods, some help needed 
       3-food must be cut, but can feed self 
       4-needs to be fed 
 
     Dressing 
       0-normal 
       1-somewhat slow, no help needed 
       2-occasional help with buttons or arms in sleeves 
       3-considerable help required but can do something alone 
       4-helpless 
 
     Hygiene 
       0-normal 
       1-somewhat slow but no help needed 
       2-needs help with shower or bath or very slow in hygienic care 
       3-requires assistance for washing, brushing teeth, going to bathroom 
       4-helpless 
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Turning in Bed/ Adjusting Bed Clothes 
       0-normal 
       1-somewhat slow no help needed 
       2-can turn alone or adjust sheets but with great difficulty 
       3-can initiate but not turn or adjust alone 
       4-helpless 
 
     Falling-Unrelated to Freezing 
       0-none 
       1-rare falls 
       2-occasional, less than one per day 
       3-average of once per day 
       4->1 per day 
 
     Freezing When Walking 
       0-normal 
       1-rare, may have start hesitation 
       2-occasional falls from freezing  
       3-frequent freezing, occasional falls 
       4-frequent falls from freezing 
 
     Walking 
       0-normal 
       1-mild difficulty, day drag legs or decrease arm swing 
       2-moderate difficultly requires no assist 
       3-severe disturbance requires assistance 
       4-cannot walk at all even with assist 
 
     Tremor 
       0-absent 
       1-slight and infrequent, not bothersome to patient 
       2-moderate, bothersome to patient 
       3-severe, interfere with many activities 
       4-marked, interferes with many activities 
 
     Sensory Complaints Related to Parkinsonism 
       0-none 
       1-occasionally has numbness, tingling, and mild aching 
       2-frequent, but not distressing 
       3-frequent painful sensation 
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III. Motor Exam 
 
     Speech 
       0-normal 
       1-slight loss of expression, diction, volume 
       2-monotone, slurred but understandable, mod. impaired 
       3-marked impairment, difficult to understand 
       4-unintelligible 
 
     Facial Expression 
       0-Normal 
       1-slight hypomymia, could be poker face 
       2-slight but definite abnormal diminution in expression 
       3-mod. hypomimia, lips parted some of time 
       4-masked or fixed face, lips parted 1/4 of inch or more with complete loss of  
expression 
 
     *Tremor at Rest  
       Face  
         0-absent 
         1-slight and infrequent 
         2-mild and present most of time 
         3-moderate and present most of time 
         4-marked and present most of time 
 
       Right Upper Extremity (RUE)  
         0-absent 
         1-slight and infrequent 
         2-mild and present most of time 
         3-moderate and present most of time 
         4-marked and present most of time 
 
       LUE  
            0-absent 
         1-slight and infrequent 
         2-mild and present most of time 
         3-moderate and present most of time 
         4-marked and present most of time 
 
       RLE  
         0-absent 
         1-slight and infrequent 
         2-mild and present most of time 
         3-moderate and present most of time 
         4-marked and present most of time 
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       LLE  
         0-absent 
         1-slight and infrequent 
         2-mild and present most of time 
         3-moderate and present most of time 
         4-marked and present most of time 
 
     *Action or Postural Tremor 
 
       RUE 
         0-absent 
         1-slight, present with action 
         2-moderate, present with action 
         3-moderate present with action and posture holding 
         4-marked, interferes with feeding 
 
       LUE 
         0-absent 
         1-slight, present with action 
         2-moderate, present with action 
         3-moderate present with action and posture holding 
         4-marked, interferes with feeding 
 
     *Rigidity 
 
       Neck 
         0-absent 
         1-slight or only with activation 
         2-mild/moderate 
         3-marked, full range of motion 
         4-severe  
 
       RUE 
         0-absent 
         1-slight or only with activation 
         2-mild/moderate 
         3-marked, full range of motion 
         4-severe 
 
       LUE 
         0-absent 
         1-slight or only with activation 
         2-mild/moderate 
         3-marked, full range of motion 
         4-severe  
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       RLE 
         0-absent 
         1-slight or only with activation 
         2-mild/moderate 
         3-marked, full range of motion 
         4-severe 
 
       LLE 
         0-absent 
         1-slight or only with activation 
         2-mild/moderate 
         3-marked, full range of motion 
         4-severe  
 
     *Finger taps 
 
       Right 
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
       Left 
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
     *Hand Movements (open and close hands in rapid succession)  
 
       Right 
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
       Left 
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
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     *Rapid Alternating Movements (pronate and supinate hands) 
 
       Right 
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
       Left  
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
     *Leg Agility (tap heel on ground, amp should be 3 inches)  
 
       Right  
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
       Left  
         0-normal 
         1-mild slowing, and/or reduction in amp. 
         2-moderate impaired. Definite and early fatiguing, may have occasional arrests 
         3-severely impaired. Frequent hesitations and arrests. 
         4-can barely perform 
 
     *Arising From Chair (pt. arises with arms folded across chest) 
       0-normal 
       1-slow, may need more than one attempt 
       2-pushes self up from arms or seat 
       3-tends to fall back, may need multiple tries but can arise without assistance 
       4-unable to arise without help 
 
     *Posture 
       0-normal erect 
       1-slightly stooped, could be normal for older person 
       2-definitely abnormal, mod. stooped, may lean to one side 
       3-severely stooped with kyphosis 
       4-marked flexion with extreme abnormality of posture 
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     *Gait 
       0-normal 
       1-walks slowly, may shuffle with short steps, no festination or propulsion 
       2-walks with difficulty, little or no assistance, some festination, short steps or  
propulsion 
       3-severe disturbance, frequent assistance 
       4-cannot walk 
 
     *Postural Stability (retropulsion test) 
       0-normal 
       1-recovers unaided 
       2-would fall if not caught 
       3-falls spontaneously 
       4-unable to stand 
 
     *Body Bradykinesia/ Hypokinesia 
       0-none 
       1-minimal slowness, could be normal, deliberate character 
       2-mild slowness and poverty of movement, definitely abnormal, or dec. amp. of  
movement 
       3-moderate slowness, poverty, or small amplitude 
       4-marked slowness, poverty, or amplitude 
 
Scale Obtained From: National Parkinson Foundation. (2007). Hoehn and Yahr Staging 
of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab 









Hoehn and Yahr Stage of Disease Scale 
 
Stage One: 
Signs and symptoms on one side only 
Symptoms mild 
Symptoms inconvenient but not disabling 
Usually presents with tremor of one limb 
Friends have noticed changes in posture, locomotion and facial expression 
 
Stage Two: 
Symptoms are bilateral 
Minimal disability 
Posture and gait affected 
 
Stage Three: 
Significant slowing of body movements 
Early impairment of equilibrium on walking or standing 




Can still walk to a limited extent 
Rigidity and bradykinesia 
No longer able to live alone 





Cannot stand or walk 
Requires constant nursing 
 
Scale Obtained From: National Parkinson Foundation. (2007). Hoehn and Yahr Staging 
of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab 














Schwab and England Activities of Daily Living 
 
Rating can be assigned by rater or by patient.  
 
* 100%-Completely independent. Able to do all chores w/o slowness, difficulty, or 
impairment.  
 
* 90%-Completely independent. Able to do all chores with some slowness, difficulty, or 
impairment. May take twice as long.  
 
* 80%-Independent in most chores. Takes twice as long. Conscious of difficulty and 
slowing  
 
* 70%-Not completely independent. More difficulty with chores. 3 to 4X along on 
chores for some. May take large part of day for chores. 
 
* 60%-Some dependency. Can do most chores, but very slowly and with much effort. 
Errors, some impossible  
 
* 50%-More dependant. Help with 1/2 of chores. Difficulty with everything  
 
* 40%-Very dependant. Can assist with all chores but few alone  
 
* 30%-With effort, now and then does a few chores alone of begins alone. Much help 
needed  
 
* 20%-Nothing alone. Can do some slight help with some chores. Severe invalid  
 
* 10%-Totally dependant, helpless  
 
*  0%-Vegetative functions such as swallowing, bladder and bowel function are not 
functioning. Bedridden. 
 
Scale Obtained From: Gillingham FJ, Donaldson MC, eds., (1969). Third Symposium of 








Global Rating Scale 
 
Subject’s name: _____________________________  Date:________________  
Number of Months After Surgery:_______________  
 
Please give us your own evaluation of how you are doing compared to what you 
remember how you were prior to the surgery. 
 
 Markedly worse.  Very unhappy with results. (-3) 
 
Definitely worse. Unhappy with results.   (-2) 
 
 Slightly worse, but not significantly.   (-1) 
 
 No change.       ( 0) 
 
 Slightly improved, but no significantly.   (+1) 
 
 Moderately improved. Happy with results.   (+2) 
 
 Markedly improved. Very happy with results.  (+3) 
 
 
   My Score Is:_________  
 
Do you think you received the fetal transplant? Y N Don’t Know 
 (Circle One) 
 
Any other Comments:____________________________________________________  
 
Measure Obtained From: McRae, C., Cherin, E., Yamazaki, T. G., Diem, G., Vo, A. H., 
Russell, D. W., Ellgring, J. H., Fahn, S., Greene, P. Dillon, S., Winfield, H., & Freed, C.  
(2004).  Effects of perceived treatment on quality of life and medical outcomes in a 










Center for Epidemiologic Studies Depression Scale (CES-D) 
 
 
0= Rarely or none of the time (less than 1 day) 
1= Some or a little of the time (1-2 days) 
2= Occasionally or a moderate amount of the time (3-4 days) 
3= Most or all of the time (5-7 days) 
 
During the past week….. Circle One 
1.    I was bothered by things that usually don’t bother me. 0  1  2  3  
2.    I did not feel like eating; my appetite was poor. 0  1  2  3 
3.    I felt that I could not shake off the blues even with help from my       
              family/friends. 
 
0  1  2  3 
4.    I felt I was just as good as other people. 0  1  2  3 
5.    I had trouble keeping my mind on what I was doing. 0  1  2  3 
6.    I felt depressed. 0  1  2  3 
7.    I felt that everything I did was an effort. 0  1  2  3 
8.    I felt hopeful about the future. 0  1  2  3 
9.    I thought my life had been a failure. 0  1  2  3 
10.    I felt fearful. 0  1  2  3 
11.    My sleep was restless. 0  1  2  3 
12.    I was happy. 0  1  2  3 
13.    I talked less than usual. 0  1  2  3 
14.    I felt lonely. 0  1  2  3 
15.    People were unfriendly. 0  1  2  3 
16.    I enjoyed life. 0  1  2  3 
17.    I had crying spells. 0  1  2  3 
18.   I felt sad. 0  1  2  3 
19.   I felt that people disliked me. 0  1  2  3 
20.   I could not get going. 0  1  2  3 
 
SCORING: zero for answers in the first column, 1 for answers in the second column, 2 
for answers in the third column, 3 for answers in the fourth column.  The scoring of 
positive items is reversed.  Possible range of scores is zero to 60, with the higher scores 
indicating the presence of more symptomatology. 
 
Scale Reformatted from: Radloff, L. S. (1977). The CES-D scale: A self-report 
depression scale for research in the general population. Applied Psychological 
Measurement, 1, 385- 401. 
 
 





Social Provisions Scale (SPS) 
 
Instructions: In answering the following questions, think about your current relationships 
with friends, family members, co-workers, community members, and so on.  Please indicate 
to what extent each statement describes your current relationships with other people.  Use 
the following scale to indicate your opinion:  
 
  1    2            3        4  
     Strongly Disagree     Disagree     Agree Strongly   Agree  
 
So, for example, if you feel a statement is very true of your current relationships, you would 
respond with a 4 (strongly agree).  If you feel a statement clearly does not describe your 
relationships, you would respond with a 1 (strongly disagree).   
 
1. There are people I can depend on to help me if I really need it.  
2. I feel that I do not have close personal relationships with other people.*  
3. There is no one I can turn to for guidance in times of stress.*  
4. There are people who depend on me for help.  
5. There are people who enjoy the same social activities I do.  
6. Other people do not view me as competent.*  
7. I feel personally responsible for the well-being of another person.  
8. I feel part of a group of people who share my attitudes and beliefs.  
9. I do not think other people respect my skills and abilities.*  
10. If something went wrong, no one would come to my assistance.*  
11. I have close relationships that provide me with a sense of emotional security and well-
being.  
12. There is someone I could talk to about important decisions in my life.  
13. I have relationships where my competence and skill are recognized.  
14. There is no one who shares my interests and concerns.*  
15. There is no one who really relies on me for their well-being.*  
16. There is a trustworthy person I could turn to for advice if I were having problems.  
17. I feel a strong emotional bond with at least one other person.  
18. There is no one I can depend on for aid if I really need it.*  
19. There is no one I feel comfortable talking about problems with.*  
20. There are people who admire my talents and abilities.  
21. I lack a feeling of intimacy with another person.*   
22. There is no one who likes to do the things I do.*  
23. There are people I can count on in an emergency.  
24. No one needs me to care for them.*  
 
*Indicates item should be reverse scored before computing scale total.  
SPS subscales:  
Attachment is emotional closeness from which one derives a sense of security (11, 14, 17, 
21)  
Social integration is a sense of belonging to a group that shares similar interests, concerns, 
and recreational activities (2, 5, 8, 22)  
Opportunity for nurturance is the sense that others rely upon one for their well-being (4, 7, 
15, 24)  
Reassurance of worth is recognition of one's competence, skills, and value by others (6, 9, 
13, 20)  
Reliable alliance is assurance that others can be counted upon for tangible assistance (1, 10, 
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18, 23)  
Guidance is advice or information (3, 12, 16, 19) 
 
Scale Obtained From: Cutrona, C. E., & Russell, D. W. (1987). The provisions of social 
relationships and adaptation to stress. Advances in Personal Relationships, 1, 37-67.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
